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Abstract
The Doha Declaration on the World Trade Organization's (WTO) Agreement
on Trade Related Intellectual Property Rights (TRIPS) and Public Health is a
strong political statement, which further confirms the interpretative value of
* Burcu Kilic is an expert on legal, economic and political issues surrounding intellectual property law & policy, trade, development and innovation. She provides technical and legal assistance to
governments and civil society groups around the world and promotes their participation in international
rule making. She has performed research and written extensively on these subjects. Her latest book
"Boosting Pharmaceutical Innovation in the Post-TRIPS Era; Real Life Lessons for the Developing
World" illustrates the critical role that intellectual property strategies play within access and innovation. I
wish to thank my current & former colleagues at Public Citizen's Global Access to Medicines Program;
Peter Maybarduk, Steve Kneivel, Mi Kyoeng Kim, Tiffany Jang & Adriana Benedict deserve a special
mention for their time and efforts.
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TRIPS. According to Paragraph 4 of the Doha Declaration, Members can and
should interpret and implement TRIPS in a manner supportive of their own rights
to protect public health and, in particular, to promote access to medicines for all.
The 'spirit of Doha' represents this broad consensus of the international community that governments are not only entitled to but have a duty to use the necessary
public policy health safeguards - so called TRIPS flexibilities - that are necessary to protect public health and promote access to affordable medicines.
The recent rise of bilateral and multilateral free trade agreements (FTAs)
threatens public health and access to affordable medicines. FTAs usually include
provisions that mandate an increased level of intellectual property protection and
strengthened terms of enforcement.
The United States Trade Representative (USTR) is currently negotiating the
Trans-Pacific Partnership (TPP), a multilateral free trade agreement with twelve
countries in the Asia Pacific region. The negotiations include the U.S., Japan,
Australia, Peru, Malaysia, Vietnam, New Zealand, Chile, Singapore, Canada,
Mexico, and Brunei.
The intellectual property chapter proposed by USTR includes measures harmful to access to affordable medicines that have not been seen before in previous
FTAs. They limit public health policy space in the Asia-Pacific region and disregard the spirit of Doha Declaration.
I.

Introduction

The Agreement on Trade Related Aspects of Intellectual Property Rights
(TRIPS) stands as a powerful symbol of the globalization of intellectual property
rights (IPRs). TRIPS, the first multilateral agreement that expressly links intellectual property (IP) to trade, was introduced during the final part of the Uruguay
round of the World Trade Organization (WTO) negotiations. The Agreement
covers a wide range of IP issues, including provisions on domestic enforcement
and a procedure for achieving binding dispute settlements between Parties.
TRIPS is unique in character as it establishes a minimum standard for IPRs protection for all WTO members.
Over the last decade, there have been a number of heated discussions and
debates revolving around the TRIPS Agreement. These debates have usually centered on the implementation of the TRIPS Agreement at a domestic level, as well
as its potential impact on development and the subsequent costs of compliance,
including access to affordable medicines. According to the Doha Declaration,
Members can and should interpret and implement TRIPS in a manner supportive
of their own rights to protect public health and, in particular, to promote access to
medicines for all. The 'spirit of Doha' represents the broad consensus of the
international community that governments are not only entitled to, but also have
a duty to use the necessary public policy health safeguards - the so called TRIPS
flexibilities - which are necessary in order to both protect public health and promote access to affordable medicines.
On the other hand, the recent rise of bilateral and multilateral free trade agreements (FTAs) shrink policy space for public health and access to affordable
24
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medicines. FTAs usually include provisions that mandate an increased level of IP
protection and strengthened terms of enforcement. Hence, the title of 'TRIPSplus' has emerged in reference to provisions that either exceed the requirements
of TRIPS or eliminate the flexibilities underpinning TRIPS.
The Trans-Pacific Partnership is President Barack Obama's signature AsiaPacific economic project - covering roughly half the world's population. The
current negotiations include twelve countries: the U.S., Japan, Australia, Peru,
Malaysia, Vietnam, New Zealand, Chile, Singapore, Canada, Mexico, and Brunei. The intellectual property chapter proposed by the U.S. Trade Representative
(USTR) includes measures harmful to access to medicines in several chapters of
the TPP that have not been seen before in previous FTAs. Leaked texts have
revealed U.S. demands that would significantly expand the scope of pharmaceutical patents and lower patentability criteria lengthen pharmaceutical monopolies
and eliminate safeguards against patent abuse. These risks combined make the
TPP especially dangerous for access to affordable medicines as they limit public
health policy space in the Asia-Pacific region and disregard 'the spirit of Doha
Declaration.'
This paper gives an account of the developments that have shaped the intellectual property landscape. The first part of the paper outlines the origins and background of the TRIPS Agreement and the Doha Declaration. The second part
focuses on the TPP and summarizes the TRIPS-plus provisions of the U.S. proposal for the IP chapter of the TPP.
II.

The TRIPS Agreement

A.

The Origins of the TRIPS Agreement

The roots of the TRIPS Agreement begin in the Paris Convention for the Protection of Industrial Property (1883)' and the Berne Convention for the Protection of Literary and Artistic Works (1886).2 These conventions established the
basic legal principles of IPRs regarding non-discrimination, national treatment,
and right of priority for ultimate global protection of IPRs. Remarkable advances
in technology during the 1980s, including the effective utilization of computers,
led to a surge of technological developments. Computer-aided drug design allowed pharmaceutical companies to discover new molecules and compounds
through random screening of natural products. This use of computer technology
enabled inventors to introduce new inventions to the market more rapidly than

I The provisions of the Paris Convention enabled inventors to obtain protection in foreign territories
for their intellectual creations in the form of industrial property rights and inventions (e.g. patents, trademarks and industrial designs). See Paris Convention for the Protection of Industrial Property, Mar. 20,
1883.
2 The Berne Convention brought copyright into the international arena. Berne made it possible for
nationals of signatory states to obtain international protection of their right in relation to controlling and
receiving payment for the use of their creative works. See Berne Convention for the Protection of Literary and Artistic Works, Sept. 9, 1886.
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ever before. 3 The effective protection of IPRs became relatively favourable and
advantageous for pharmaceutical companies and developed countries.
Patents are one of the oldest forms of intellectual property protection. As with
all forms of intellectual property, patent protection is justifiable as being primarily a neutral social mechanism that enables an adequate allocation of private
sources to encourage the creation of technology.4 In highly industrialized and
developed countries, patent systems are used as regulatory tools to stimulate investment in research and development (R&D) and innovation. Over the last few
decades, patents were made more available and easier to obtain for a wider variety of goods in those countries.
By the end of the 1980s, multinational pharmaceutical companies made the
international protection of IPRs a high priority. Numerous studies noted the economic losses suffered by major companies due to the lack of effective protection
and/or enforcement of IPRs abroad, especially in the major developing countries. 5 The relatively weak IPRs protection in developing countries started to be
seen as a trade-related problem by multinational pharmaceutical companies and
governments of developed countries. Multinational companies demanded a uniform system that would provide strong worldwide protection, which led to the
collaboration of the three leading lobbying groups - entertainment, software, and
pharmaceutical industries. They shared a common interest in fortifying the protection of IPRs worldwide, because their success relatively depended upon the
collection of economic royalties that accrue from IPRs protection. They had the
political muscle to place IPRs prominently on the U.S. trade agenda.6
Taking all these concerns into account, the U.S. Congress incorporated IPRs
into the U.S. trade regime. Relatively weak IPRs protection in developing countries was identified as one of the major causes for trade distortion and the consequent export losses. The protection of IPRs was afforded more favourable
treatment than the apparent public interest in the availability of affordable
medicines.
Consequently, Section 301 of the U.S. Trade Act of 1984 introduced IPRs into
the U.S. trade agenda, which was designed to provide for the enforcement of
trade sanctions against foreign countries for maintaining acts, policies and practices that violate or deny U.S. rights and benefits under trade agreements, or that
are unjustifiable, unreasonable, discriminatory and have the potential to restrict
U.S. commerce. By the authority given under Section 301, USTR undertook an
investigation of allegations of IP infringement. 7
3 BURCu KiiCi, BOOSTING PHARMACEUICAL INNOVATION IN THE Posr-TRIPS ERA; REAl. LIFi LU-sSONS FOR THE DEVELOPING WoMnt 68-72 (2014).
4 NUNO PIRES DE CARVALHo, THE TRIPS REGIME OF PATENr RIGHTS I (2d ed., 2005).
5 GLOBAL DIMENSIONS OF INTELLECIuAL PROPERTY RIGHTS IN SCIENCE ANi) TECHNOLOGY 12-22
(Mitchel B. Wallerstein et al. eds., 1993).

6 Kenneth C. Shadlen, Intellectual property, trade, and development: can foes be friends? 13
GLOBAL GOVERNANCE 171, 172 (2007).

7 Susan K. Sell, Intellectual Property Protection and Antitrust in the Developing World: Crisis,
Coercion, and Choice, 49 INT'l ORG. 315, 323 (1995).
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Nevertheless, Section 301 did not go far enough to assure global protection for
IPRs at the desired level. Following failure of these bilateral efforts, the process
moved to a multilateral setting.
B.

Intellectual property and trade - hand in hand for new beginnings

The World Intellectual Property Organisation (WIPO) was the primary regulative organ for the administration of the main IPRs treaties, such as the Paris
Convention on Industrial Property and the Berne Convention on Literary and
Artistic Works. The standards established by these WIPO treaties failed to provide substantive protection and crucially, the WIPO system lacked proper enforcement mechanisms.
The reviews of the Paris Convention, which took place in the early 1980s,
ended in a fiasco for developed countries. It had become obvious that the proposals to strengthen the WIPO system of IPRs protection were not practical enough
to meet the needs of an effective, global IPRs regime. Given the lack of tangible
results achieved during that period, developed countries, led by the U.S., substantially redefined their interests and changed their approach. 8
These developed countries adopted a trade-based approach not overseen by
WIPO. The U.S. was the first member to propose the inclusion of IPRs within the
agenda of the General Agreement on Tariffs and Trade (GATT). As part of the
Ministerial Declaration of 1986, the Uruguay round of negotiations on the traderelated aspects of intellectual property was launched. 9
The goal was to draft a multilateral binding agreement that would set minimum levels of protection and enforcement for IPRs. The variable WIPO regime
was replaced with a more robustly governed multilateral regime that set a minimal floor level for protection of IPRs.' 0 Hence, the developed countries, led by
the U.S., envisaged an ambitious and comprehensive agreement on standards for
the protection of IPRs.
The Uruguay round of negotiations was based on incomplete information and
as a result, it was regarded as an 'imperfect bargain' 1 1 for developing countries.
They were willing to "co-operate on the former, but opposed the latter"' 2 and
were unable to form a cohesive group. In fact, developing countries were individually weak and divided as a group. There was a vast gap regarding both intellectual knowledge and negotiation resources between the developed and developing
countries. While most of the developing countries were represented by a limited
8 Daniel J. Gervais, The Internationalizationof Intellectual Property: New Challenges From the
FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 929, 934 (2002).

Very Old and the Very New, 12

9 DUNCAN MATFHEWS, GLOABLISING

INTELLECTUAL

PROPERTY RIGHrs:

THE TRIPS

AGREEMENT

17

(Richard Higgott ed., 2002).

10

CHRISTOPHER MAY, THE WORLD INTELLECTUAL PROPERTY ORGANIZATION, RESURGENCE AND THE

DEVELOPMENT AGENDA 68 (2007).

li For

TRIPS negotiation

narrative, see DANIEL GERVAIS, INTELLECTUAL PROPERTY TRADE AN) DETRIPS-PLus ERA (2007).
M. HOEKMAN & MICHEL M. KOSTECKl, THE POLITICAL ECONOMY OF THE WORLD

VELPMtoTr, STRATEGIES 10 OPTIMIZE ECONOMIC DEVELOPMENT IN A
12 BERNARD

TRADE SYSTEM

283 (2nd ed. 2001).
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number of negotiators, the U.S. had dozens of negotiators who were solely working on the issue of IPRs alone.1 3 At the time, the negotiation process was described as "a lopsided affair; it is like a war where some people fight with pistols
while the others engage in aerial bombardment."' 4 Developing countries simply
did not have the technical expertise to negotiate the issue. Furthermore, there was
a lack of motivation and coordination among developing countries. They were
unable to "foresee how far reaching the economic and social implications of the
TRIPS Agreement were likely to be."i5 Combined with "hardball" diplomacy,
this enabled developed countries to 'win the battle' and achieve the first global
governance regime for IPRs as a part of the new WTO system.16
In contrast to the rest of the Uruguay round, the TRIPS negotiations were
focused not on freeing trade but on changing the domestic regulatory and legal
regimes in developing countries.' 7 At this stage, the TRIPS negotiations were
assumed to be zero-sum in the short run because it was thought that the stronger
enforcement of rights in developing countries could result in large transfers of
foreign direct investment.' 8 There were a number of possible gains to be made in
relation to world trade, since each group of countries was able to offer something
that the other group of countries wanted.
It is possible to view TRIPS as unique because of the way it was negotiated.
There was a strategy to get a mix of issues on the table, even if they were previously unrelated, in order for them to become linked for bargaining purposes. This
was known as 'linkage-bargain diplomacy.'l9 Thus, IP was negotiated across sectors. Put simply, it was traded in negotiations for deals on fruits or textiles.
Hence, GATT offered opportunities to create bargaining positions and many developing countries had much to gain from a liberalized trade regime, which had
the ability to incorporate textiles and agricultural products. The fear of being
undercut by competitors in the developing world meant that some of the poorer
nations were forced to tighten their domestic protection of IPRs unitarily in order
to attract foreign direct investment and technology and to avoid the U.S. trade
sanctions 20. On the other hand, the U.S. and other developed countries had much
to gain from the liberalization of services and strong worldwide IP protection. 2 1
Thus, TRIPS was considered to be the product of a compromise between developed and developing countries. However, the bargaining power of the parties was
13 HA-JOON CHANG, BAD SAMARITANS: THE GUILTY SECRETS OF RICH NATIONS AND THE THREAT TO

GLOBAL PROSPERITY 37 (2007).
'4 Id.

15 See MATTHEWS, supra note 9, at 44-45.
16 CHRISTOPHER MAY & SUSAN SELL: INTELLECTUAL PROPERTY RIGHTS: A CRITICAL HISTORY 158

(2006).
17 See HOEKMAN & KOSTECKI, supra note 12, at 284.
18 Id.
19 MICHAEL P. RYAN, KNOWLEDGE DIPLOMACY: GLOBAL COMPETITION AND THE POLITICS OF INTELLECTUAL PROPERTY 92 (1998).
20 BERNARD

M.

HOEKMAN

&

MICHEL M. KOSTECKI, THE POLITICAL ECONOMY OF THE WORLD TRAD-

ING SYSTEM 284 (2nd ed. 2001).
21 Id.
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far from equal. 22 It was "the opportunity to obtain multilateral rules and enforcement mechanisms across so many disparate issues [that was] likely to be viewed
as one of the major accomplishments in any concluded the Uruguay Round." 2 3
According to legal scholars, the TRIPS method of dictating rules to countries,
whether developed, developing or least-developed, regarding what they must do
and when and how they must do it, was unprecedented in multinational treaties.
As a result, there has been widespread discussion over whether this will have farreaching effects on national legal systems to an extent that goes far beyond the
realms of intellectual property. 24
C.

A Beginning of the New Era

TRIPS may be described as a 'constitution like' agreement because it contains
more than mere 'wishes,' 2 5 it reaches into the nation-state, giving rights to individuals. 2 6 However, there is still some room for flexibility regarding the way the
protected subject matter is defined, owned, managed and made subject to
exceptions. 2 7
The main objective of the Agreement is "to reduce distortions and impediments to international trade." 28 The need to provide adequate IPRs standards has
been recognised. However, there should be a balance between the interests of the
public in access to information and technology and the interests of those creating
new works and inventions in securing a return on their investment. This is necessary in the context of trade to avoid distortion of the system. It follows that
TRIPS can only survive as an instrument of international public policy to an
extent that the balance between these competing interests is established. 29
TRIPS establishes 'minimum standards' of IPRs; however the implementation
of the provisions was left to the member states' own discretion. 0 Thus, the
Agreement was not recognized as being 'self-executing' or having 'direct effect.'
However, Members are given the opportunity to adopt a more extensive protection than what is required, provided that such protection does not contradict the
provisions of TRIPS.
The Agreement allows for diversity in the implementation methods of the provisions. The way in which it is implemented may have important implications
22 Peter K. Yu, TRIPS and Its Discontents, 10 MARQ. INTELL. PROP. L. REv. 370, 371 (2006).

23 Dunkel, In "Draft Final Act Embodying the Results of the Uruguay Round of Multilateral Trade
Negotiations", GATT DOC.MTN.TNCIW/FA (20 December 1991).
24 Gerald J. Mossinghoff, National Obligations Under Intellectual Property Treaties: The Beginning
of a True InternationalRegime, 9 FED. IR. B.J. 591, 603 (2000).
25 See GERVAIS, supra note II at 25.
26 Steve Charnovitz, The WTO and the Rights of the Individual 36 INTERE-coNoMics, 98, 98 (2001).
27 See GERVAIS, supra note 11 at 25.
28 TRIPS: Agreement on Trade-Related Aspects of Intellectual Property Rights, Preamble, available
at http://www.wto.org/english/tratop-e/trips-e/t-agml-e.htm.
29 See GERVAIS, supra note I1, at 24-25.
30 TRIPS Agreement, Art. 1.1 ("Members shall be free to determine the appropriate method of implementing the provisions of this Agreement within their own legal system and practice.").
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regarding the conditions for the access to and the use of technology, as well as
for the economic and social development particularly in developing countries. 3 1
TRIPS is widely regarded as a means for the realization of public policy objectives via the 'inducement to innovation' and therefore, the access to the results
thereof by those who need them. 3 2 The Agreement makes an explicit reference to
"the promotion of technological innovation and to the transfer and dissemination
of technology, to the mutual advantage of producers and users of technological
knowledge." 3 3 The reference to mutual advantage of producers and users represents a compromise between developed and developing countries.
D.

The Post-TRIPS Era and the Doha Declaration

Through their signature of TRIPS, the member states effectively gave up significant elements of their own sovereignty regarding the essential features of polity, i.e. the relevant administrative and judicial structures and procedures. 3 4
The Agreement still remains an effective compromise between developed and
developing countries over the scope of IPRs protection. It attempts to balance the
needs and desires of all the members in order to harmonize the world IPRs regime, particularly the patent systems. However, doubt still remains regarding
whether conflict has surpassed compromise.
The implementation of the Agreement was a painful process for those countries that were not in a position to absorb the deadweight losses that resulted from
the global protection of IPRs.3 5 This gave rise to serious problems. In other
words, the strategy of the Agreement represented an unprecedented experiment
that effectively accelerated the introduction of higher IPRs standards into countries that would not ordinarily be expected to adopt them. 3 6
TRIPS was highly ambitious; it was presented to developing countries as an
instrument for securing a long-term interest towards the goals of sustainable development and innovation. However, not long after the singing of the Agreement,
its controversial provisions gave rise to discussions that focused on the costs and
side effects. To a great extent, the patent regime has been linked to rising healthcare costs and problems regarding access to medicine. Many developing countries, especially the least developed ones, were faced with public health crises.
These countries have experienced the difficulties related to the increasing prices
of medicines. It became evident that patents substantially delayed market entry of
generic medicines, raising costs and reducing access. As a result, the Agreement
has come under fierce criticism.
31 CARLOS

M.

CORREA, TRAiDE RELATED ASPECrs OF INTELLECTUAL PROPERTY RiGHTs: A COMMEN-

TARY ON THI TRIPS AGREEMENT 23 (1998).
32 Id. at 94.
33 DANIEL J. GERVAIS, THE TRIPS AGREEMENT: DRAFTING HISTORY AND ANALYSIS

117 (2003).

34 RYAN, supra note 19, at 143.

35 David W. Opderbeck, Patents, Essential Medicines, and the Innovation Game, 58 Vanderbilt L.
Rev. 501, 507 (2005).
36 KarfH E. MASKUS, INTELLECTUAL PROPERTY RIGHTS IN THE GLOBAL ECONOMY 144 (2000).
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Clearly, when the developing countries signed the TRIPS Agreement, they
conceded more than they received. For instance, the TRIPS assumptions and expectations regarding the technological self-sufficiency of developing countries
have proven to be inaccurate.3 7 This contributed directly to a number of health
crises around the globe.3 8 Thus, the enactment of TRIPS led to a wide-ranging
debate regarding the positive and negative sides of introducing strong IPRs in
developing countries. 39 These concerns have historically played an inordinate
role in shaping changes to the political landscape.
In this context, the WTO's Fourth Ministerial Conference in Doha, Qatar, in
November 2001 (the Doha Round) reflected the concerns of developing countries. The Ministerial Conference produced a separate Declaration on TRIPS and
Public Health. 4 0 It was a strong political statement, which provided a mandate for
Parties on the implementation of TRIPS by affirming its interpretative value. 4 1 It
aimed to establish a balance between the need for access to medicines and creating incentives for innovation. 42
The main purpose of the Declaration was to clarify the uncertainty that had
arisen in many developing countries surrounding the use of TRIPS flexibilities,
as most of the developing countries lack the experience and administrative knowhow to regulate patents. Furthermore, the political and administrative systems of
developing countries were not mature enough to face the challenges of the patent
system.
Thus, Paragraph 4 of the Doha Declaration clarified that the Members can and
should interpret and implement TRIPS in a manner supportive of their own rights
in order to protect public health and, in particular, to promote access to medicines
for all.
"We agree that the TRIPS Agreement does not and should not prevent Members from taking measures to protect public health. Accordingly, while reiterating
our commitments to the TRIPS Agreement, we affirm that the Agreement can
and should be interpreted and implemented in a manner supportive WTO Members' rights to protect public health and, in particular, to promote access to
medicines for all." 43
The wording of the text was drafted ambiguously enough to satisfy priorities
of developing and developed countries. The existing legal obligations were main37 Id.

38 Jerome H. Reichman & Rochelle Cooper Dreyfuss, Harmonization Without Consensus: Critical
Reflections on Drafting a Substantive Patent Law Treaty, 57 DUK, L.J. 86, 97 (2005).
39 Walter G. Park, Chapter 9 Intellectual Property Rights and International Innovation, INrT-.IcTUAL PROPERTY, GROWTH, AND TRADE 289, 295 (Keith E. Maskus ed., 2007).

40 World Trade Organization, Ministerial Declaration of 14 November 2001, WT/MIN(01)/DEC/2,
41 I.L.M. 755 (2002).
41 Carlos M. Correa, Multilateral Agreements and Policy Opportunities, available at http://policy
dialogue.org/files/events/CorreaMultilateral-Agreements-andPolicy-Opportunities.pdf.

I1, at 8.
43 World Trade Organization, Ministerial Declaration of 14 November 2001, WT/MIN(01)/DEC/2,
41 I.L.M. 755 (2002).
42 GERVAIS, supra note
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tained, however the importance of public health over private interests of right
owners had been vindicated. 4 4
TRIPS was regarded as a form of "nodal governance." 4 5 In this system, the
powerful groups built up an ever-increasing circle of influence, arguably
achieved through the use of trade coercion. Hence, the Doha Declaration may be
appreciated as a victory for developing countries. They managed to isolate the
U.S. and its pharmaceutical industry during the negotiations. 4 6
The Declaration was a strong political statement, demonstrating that when a
group of countries does not feel that a treaty has given them a fair deal, they
could continue the political fight at a later date.4 7
The spirit of Doha represents this broad consensus of the international community that governments are not only entitled to but have a duty to use the necessary
public policy health safeguards - so called TRIPS flexibilities necessary to protect public health and promote access to affordable medicines. These flexibilities
should not only be implemented in domestic legislation but they should also be
safeguarded against IP provisions that negatively affect access to medicines.
]E.

TRIPS-plus provisions & Free Trade Agreements

The three leading industries in the U.S. were not entirely satisfied with the
terms of TRIPS or the compromises given to the developing countries as a part of
the Doha Declaration. 4 8 TRIPS set certain minimum standards for IP protection,
but the industries wanted more.
The multinational WTO negotiations in the public eye, coupled with the increasing public awareness of access to affordable medicines, necessitated a forum shift. 4 9 In the late '90s, closed-door non-transparent FTA negotiations
emerged as a better venue for continuing global IP norm setting.
The FTAs usually include provisions that mandate an increased level of IP
protection and strengthened terms of enforcement going beyond the requirements
of TRIPS50 . Hence, the title of TRIPS-plus has started to be used widely in reference to provisions that either exceed the requirements of TRIPS or eliminate the
flexibilities underpinning TRIPS.
The recent rise of bilateral and multilateral FTAs threatens public health and
access to affordable medicines. Strong trade and power asymmetries exist be44 J. Michael Finger, The Doha Agenda and Development: A View from the Uruguay Round 19,
(Asian Development Bank, ERD Working Paper Series No. 21, 2002).
45 Scott Burris et al., Nodal Governance, 30 Australian Journal of Legal Philosophy, 30, 46 (2005).
46 Peter Drahos, Expanding Intellectual Property's Empire: the Role of FTAs, GRAIN 1, 11 (2003)
http://www.grain.org/rights-files/drahos-fta-2003-en.pdf.
47 Id. at 9.
48 CHARAN DEVEREAUX ET. AL., CASE STUDIES IN US TRADE NEGOTIATION, VOLUME 1: MAKING THE
RULES 75 (2006).
49 See SUSAN K. SELLs, PRIVATE POWER, PuBUc LAW: THE GLOBALIZATION OF INTELLECIUAI. PROrERTY RIGHTS (Steve Smith et al. eds., 2003).
50 Carsten Fink & Patrick Reichenmiller, Tightening TRIPS: Intellectual Property Provisions of U.S.
Free Trade Agreements, in Trade, Doha, and Development: Window into the Issues (2006).
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tween developed and developing countries during FTA negotiations. The tradeoriented pressures applied to developing countries to far surpass the protection
afforded by TRIPS and to diminish the system of the TRIPS flexibilities in order
to fall in line with the ill-suited 'TRIPS-plus' solutions.5 1
Since 1994, the U.S. has signed twenty FTAs with both developed and developing countries including Jordan, Morocco, Peru, Chile, Australia, and Singapore. 52 These agreements introduce substantive patent and enforcement rules and
each agreement updates the previous one and sets the bar higher for IP protection
for countries that aim to engage in negotiations to establish bilateral and regional
FTAs with the U.S. 5 3 and EU. 5 4 In addition to influencing the IP regimes of FTA
parties, they also exert normative influence at the international level.
In fact, the increasing number of FTAs, or bilateral investment treaties, shows
that the TRIPS Agreement is being increasingly marginalized, even though its
passing has not been made official.5 5
III.

Trans-Pacific Partnership

USTR is currently negotiating the Trans-Pacific Partnership Agreement (TPP)
with eleven countries in the Asia-Pacific region including Vietnam, Malaysia,
Brunei Darussalam, Singapore, Australia, New Zealand, Peru, Chile, Canada,
Mexico and Japan. 5 6 Over time, the U.S. hopes to eventually expand the TPP's
reach to the entire Asia-Pacific Region - comprising roughly forty percent of the
world's population, fifty-five percent of global GDP, and some of the world's
fastest growing economies.5 7 According to President Obama the TPP is "a real
model, not only for the region but for the world.5 8
The origins of the TPP go back to a little known Trans-Pacific Strategic Economic Partnership (P4) Agreement, a FITA signed between New Zealand, Chile,
51 SELLS,

supra note 49.

See Free Trade Agreements, Office of the U.S. Trade Representative, available at http://www.ustr
.gov/trade-agreements/free-trade-agreements.
52

53 The U.S. has free trade agreements in force with 20 countries. Free Trade Agreements, Office of
the United States Trade Representative, available at http://www.ustr.gov/trade-agreements/free-tradeagreements.

-

54 The EU has free trade agreements in force with 29 countries. The EU's free trade agreements
where are we?, European Commission, available at http://europa.eu/rapid/press-releaseMEMO-12-932
en.htm?locale=EN

55 Mohammed El-Said, Editorial: Free Trade Intellectual Property and TRIPS-Plus World, 28 Liverpool L.R. 1, 8 (2007) (discussing TRIPS becoming increasingly marginalized).
56 See Trans-Pacific Partnership (TPP), available at http://www.ustr.gov/tpp
57 What is Asia-Pacific Economic Cooperation?, ASIA-PACIFIC ECONOMIC COOPERATION,
http://www.apec.org/About-Us/About-APEC.aspx.
58 Statements by President Barack Obama and Prime Minister of Canada Stephen Harper of Canada,
The White House Office of the Press Secretary (December 6, 2011), available at http://www.whitehouse
.gov/the-press-office/2011/12/07/statements-president-barack-obama-and-prime-minister-canadastephen-harp.
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Singapore and Brunei in 2006.59 In 2009, USTR announced that the U.S. would

be joining the expanded Trans-Pacific Partnership to negotiate a comprehensive
and high-standard trade agreement for the Asia-Pacific region. 60 Australia, Peru,
Singapore, Malaysia and Vietnam also eventually joined the partnership. 6 1 The
first round of official negotiations took place in Melbourne, Australia in March
of 2010.62 The U.S. took the driver's seat afterwards for agenda setting and
proposal submissions.
By late 2010, it became clear that the TPP would not be an ordinary trade
agreement introducing more simplified and transparent trade and investment procedures in the Asia-Pacific region. Rather, it would impose expansive policy and
regulatory constraints on the signatory countries. 63 USTR aimed at going far beyond trade facilitation and to deeper integration in IP, public health policies, custom regulations, consumer rights, and other issues of public concern. It has been
made clear that the TPP would harmonize IPR obligations strictly upwards.M
USTR tabled its proposals for the IP chapter in February 2011, during the fifth
round of TPP negotiations in Santiago, Chile.65 The text was leaked by Knowledge Ecology International (KEI) in March 2011.66 The proposals were marked
as "protected from unauthorized disclosure," because they included confidential
information and were deemed classified until four years after entry into force or
close of the negotiations. 67
The U.S. proposals contained numerous provisions that go well beyond the
required standards of TRIPS. They collectively aimed for favourable conditions
for the U.S. pharmaceutical industry in the TPP countries. 68 If adopted and implemented, several of those provisions would severely limit access to affordable
medicines and treatment options in low- and middle-income countries, including
several that are parties to the TPP negotiations. 69 The proposals are widely ac59 Trans-Pacific Strategic Economic Partnership (P4) Agreement, New Zealand Ministry of Foreign
Affairs & Trade, available at http://mfat.govt.nz/Trade-and-Economic-Relations/2-Trade-Relationshipsand-Agreements/Trans-Pacific/index.php.
60 Trans-Pacific Partnership Announcement, USTR (December 14, 2009), available at http://www.
ustr.gov/about-us/press-office/press-releases/2009/december/trans-pacific-partnership-announcement.
61 See New Zealand Ministry of Foreign Affairs & Trade, supra note 59.
62 Trans-Pacific Partnership Agreement negotiations, Australian Government Department of Foreign
Affairs and Trade, available at https://www.dfat.gov.au/fta/tpp/100326-tpp-stakeholder-update-1.html.
63 Trans-Pacific Partnership (TPP): Job Loss, Lower Wages and Higher Drug Prices, Public Citizen's
Global Trade Watch, available at http://www.citizen.org/TPP.
6 See Notes from meeting with USTR on the TPP IPR chapter, Knowledge Ecology International
(KEI) (December 13 2010), available at http:/Ikeionline.org/node/1035.
65 Mike Palmedo, TPP Negotiations - US Tables Intellectual Property Text; Members of US Congress Push for Strong IP Protections; Civil Society Asks for Protection of TRIPS Flexibilities, INFOJUSnCE available at http://infojustice.org/archives/1245.
66 The Trans-Pacific Partnership, Intellectual Property Rights Chapter, Draft- February 2011, available at http://keionline.org/sites/default/files/tpp-10feb20 11-us-text-ipr-chapter.pdf.
67 See id.
68 For more information on the TPPA, see http://www.citizen.org/more-about-trans-pacific-FTA.
69 Access to Medicines in the Trans-Pacific FTA, PumLIc CIflZEN, available at http://www.citizen
.org/Page.aspx?pid=5325&frcrld=1.
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knowledged as the latest manifestation of the U.S. maximalist agenda in international intellectual property rulemaking. 70
The February text included stringent patent and enforcement rules, including
7
placeholder provisions on pharmaceutical related IP provisions. ' The
placeholder text was tabled in September 2011 during the eighth round of negotiations in Chicago, U.S., with a white paper outlining the Obama Administration's
plans to harmonize trade and IP policies with TPP partners in order to protect and
promote access to medicines. 7 2 The Trade Enhancing Access to Medicines
("TEAM") approach is presented as fresh thinking, which aims to "deploy the
tools of trade policy . . . to help reduce potential barriers to access to medicines,
while also supporting innovation and the development of new medicines by the
U.S. pharmaceutical and other health industries." 73
Despite these positive intentions expressed on paper, the simultaneous release
of the TEAM paper and the most controversial and access-restricting provisions
of the TPP casted doubts among public health advocates and academics. The
paper has been subject to substantial criticisms for entirely failing to address
these access-restricting provisions of overly aggressive IP provisions. USTR's
efforts have been interpreted as back-pedalling on the promises made to the de74
veloping world on public health safeguards.
The leaks of the September 2011 text revealed that USTR has again increased
75
demands on developing countries to trade away access to affordable medicines.
There was even a significant roll back to modest New Trade Policy commitments
(the Bipartisan Agreement on Trade Policy of May 10, 2007) incorporated into
Peru, Panama, and Colombia FTAs, which ensured public health was not undermined by those FTAs.7 6 A core objective was to ensure that FTA obligations do
not put patients in developing countries in a position in which they could have to
wait longer than patients in the U.S. to obtain affordable, life-saving generic
medicines.
Indeed, the proposals tabled by USTR introduced significant 'FTAs-plus' IP
standards, which appear to be more restrictive than the ones in other FTAs signed
70 Sean Flynn et al., The U.S. Proposal for an Intellectual Property Chapter in the Trans-Pacific
PartnershipAgreement, 28 AM. U. Int'L. L. REv. 105, 108 (2013).
71 See Palmedo, TPP Negotiations, supra note 65.
72 See generally OiFicE OF THE U.S. TRADE RIPRESENTATIVE, TRANS-PACIFIC TRADE GOALS To EN-

HANCE AccEss TO MEDICINES (2011), available at http://www.ustr.gov/webfm-send/3059.
73 Id.

74 Tido von Schoen-Angerer, Shooting Itself In the Foot: The Broken Promises of the U.S. Trade
Agenda, THi WORLDPosT (Sept. 14, 2011 12:00 PM), http://www.huffingtonpost.com/tido-von-schoen
angerer/shooting-itself-in-the-fo b_959847.html.
75 See generally Trans-Pacific Strategic Economic Partnership, Intellectual Property Rights Chapter
(Selected Provisions), proposed September 2011, available at http://www.citizenstrade.org/ctc/wp-con
tent/uploads/201 1/10/TransPacificlPl.pdf.
76 A core objective was to ensure that FTA obligations do not put patients in poor countries in a
position in which they could have to wait longer than patients in the United States to obtain affordable
life saving generic medicines. OFFICE OF THE U.S. TRADE REPRESENTATIVE, BIPARTISAN AGREEMENT ON
TRADE Poi~icy 3 (May 2007), available at http://www.ustr.gov/sites/default/files/uploads/factsheets/
2007/assetuploadfile 127_11319.pdf.
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by the U.S. By prioritizing private interests over the public interest, USTR's demands aimed to strengthen, lengthen and broaden pharmaceutical monopolies,
which would lead to higher drug prices, harming access to affordable medicines
and treatment in developing countries. They imposed further limitations that
would prolong drug monopolies, eliminate local competitors, increase drug
prices, and inhibit the development of national pharmaceutical industries in the
Asia- Pacific region.
Despite the public relation efforts of the USTR, the U.S. proposals have not
escaped criticism. Doctors without Borders (MSF) called the TPP "the worst
trade deal ever with millions losing access to medicines." 77 A number of public
interest health and advocacy groups and academics have appealed the issue to the
United Nation's Special Rapporteur 78 on the right to health and asked him to
intervene into the negotiations.79 The Rapporteur requested nine of the negotiating parties of the TPP to clarify whether "some of the TPP's intellectual property
provisions would strengthen monopolies for life-saving medicines and create barriers for access to medicines" and "negatively impact the ability of developing
countries to take positive steps towards ensuring the enjoyment of the right to
health of their citizens." 80 Only Australia, Chile and New Zealand responded to
the Rapporteur and assured that they would not agree to provisions that would
negatively impact rights to health and access to medicines. 8
Considering political sensitivities, the United Nations Programme on HIV/
AIDS (UNAIDS) and the United Nations Development Programme (UNDP)
adopted a more moderate tone in criticising the TPP noting " . . . there is growing
evidence that TRIPS-plus provisions may adversely impact medicine prices and,
consequently, access to treatment." 8 2 A joint brief issued in 2012 drew attention
to the importance of TRIPS flexibilities and warned countries about the negative
consequences of TRIPS-plus provisions, proclaiming that "to retain the benefits
of TRIPS Agreement flexibilities, countries at a minimum should avoid entering
77 Doctors Without Borders, Twitter, http://www.doctorswithoutborders.org/support-us/campaigns/
trans-pacific-partnership (where Doctors Without Borders asked users to tweet U.S. Trade Representative
Michael Froman regarding the TPP).
78 SIPCIAL RAPPORTEUR TO THE UNITFED NATIONS, MANDATE OF THE SPECIAL RAPPORTEUR ON THE
RIGHT O

EVERYONE TO THE ENJOYMENT OF THE HIGHEST ATrAINABLE STANDARD OF PHYSICAL AND

MENTAL HEALTH (July 19, 2011), available at https://spdb.ohchr.org/hrdb/9th/ALUSA_19.07.2011 _%
2813.2011%29.pdf.

79 Krista Cox & Thiru Balasubramaniam, UN Special Rapporteurfor the Right to Health Asked to
Intervene in TPP Trade Negotiation, KNowEomEa
www.keionline.org/node/1099.
80 See OvFIc

OF THE U.S.

ECOLoGY INTERNATIONAL (March 21, 2011), http://

TRADE REPRESENTI-ATIViE, BIPARTISAN AGREEMENT ON TRADE POLICY,

supra note 76.
81 James Love, Australia, Chile, and New Zealand Reply to UN Rapporteurfor Right to Health on
TPP Complaints, KNOWLEDoGE ECOLOGY INTERNATIONAL (September 27, 2012), http://keionline.org/

node/554.
82 UNITED NATIONs Diy. PROGRAMME & JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS, THE
POTENTIAL IMPACT OF FRIA TRADE AGREEMENTS ON PuntLIC HEALTH 4 (2012), available at http:/www.
unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2012/JC2349-

IssueBriefFree-Trade-Agreements-en.pdf ("[Tihere is growing evidence that TRIPS-plus provisions
may adversely impact medicine prices and, consequently, access to treatment . . . .").
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into FTAs that contain TRIPS-plus obligations that can [have an] impact on
pharmaceuticals prices or availability." 83
Not surprisingly, the U.S. proposals ran into severe opposition from TPP partners. It has been reported by various sources, which have been closely following
the negotiations that eight of the negotiating parties opposed the U.S. September
text and the trade enhancing access to medicines (TEAM) approach. 84 Facing
growing opposition, the U.S. entered into a "period of reflection" in order to
internally review the feasibility of its initial proposals on patents and
pharmaceuticals. 8 5 Throughout the negotiations in 2012 and 2013, this issue became so critical that some observers feared that the deadlock of negotiations
might jeopardize a successful outcome in the TPP talks. 86
While the U.S. was in a "period of reflection," a group of six countries including Chile, New Zealand, Australia, Singapore, Malaysia and Canada" took the
driver's seat in May of 2013 during the 17th Round of negotiations in Lima,
Peru.88 They presented a discussion paper outlining an alternative approach on
pharmaceutical IP provisions to the one proposed by the U.S. 89 The paper used
the TRIPS language as a starting point for developing a legal text for the last
official round of the TPP negotiations in Brunei Darussalam in August of 2013.
The six-country proposal, which eventually became a five-country counterproposal,9 0 preserved the spirit of Doha by incorporating certain TRIPS flexibilities
to facilitate access to affordable medicines.
In November 2013, WikiLeaks published the complete draft of the IP chapter
from the Brunei Round of the negotiations. 9 1 The new leaks demonstrated that
USTR still demanded terms, which would limit access to lifesaving medicines
throughout the Asia-Pacific region. Different from the previous leaks, the
WikiLeaks text included other countries' positions and identified which countries
support which terms. The text also revealed new issues of interest and changes in
83 Id. at 5.

84 TPP Countries Poised to Revisit U.S. Access to Medicines Proposal, World Trade Online (March
8, 2013), http://insidetrade.com/Inside-Trade-General/Public-Content-World-Trade-Online/tpp-countriespoised-to-revisit-us-access-to-medicines-proposal/menu-id-896.html.
85 Id.

86 Canada, Mexico May Have Mixed Impact on U.S. Efforts on IPR in TPP, World Trade Online
(August 16, 2012), http://insidetrade.com/Inside-US-Trade/Inside-U.S.-Trade-08/17/2012/canadamexico-may-have-mixed-impact-on-us-efforts-on-ipr-in-tpp/menu-id- 172.html.
87 RICHARD BUSH

& JOSHUA

MELTZER, THE BROOKINGS lNSTrrUTION CENTER FOR EAST ASIA POLICY

STUDIES, TAWAIN AND THE TRANS-PACIFIC PARTNERSHIP: PREPARING THE WAY 5 (2013).
88 N.Z. MINISTRY OF FOREIGN TRADE AND TOURISM, TRANS-PACIFIC PARTNERSHIP NEGOTIATIONS

MOVE FORWARD IN PERU (May 24, 2013), http://www.mfat.govt.nz/downloads/trade-agreement/trans

pacific/TPP-Move-Forward-in-Peru-24May2013.pdf.
89 U.S. Tables SPS Text; Other Countries Float PharmaceuticalIP Ideas, WORLD TRADE ONLINE

(May 20, 2013), http://insidetrade.com/201305202434890/WTO-Daily-News/Daily-News/us-tables-spstext-other-countries-float-pharmaceutical-ip-ideas/menu-id-948.html.
90 Australia was in election period during the drafting of the counterproposal. Krista Cox, TPP Negotiating Parties'Counterproposalto the US on Medicines Represents a More FlexibleApproach, KNowLEDGE ECOLOGY INTERNATIONAL (November 14, 2013), http://www.keionline.org/node/1826.

91 See generally Trans-Pacific Partnership, Intellectual Property Rights Chapter, proposed August
2013, available at https://wikileaks.org/tpp/static/pdf/Wikileaks-secret-TPP-treaty-IP-chapter.pdf.
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the state of play. There were a few, but not many, helpful changes to the U.S.
position. More importantly, the publication revealed unanimous or nearly unanimous opposition to many harmful U.S. proposals, and indeed epic efforts by
some countries to advance the public interest and public domain. 92
On October 2014, WikiLeaks released a second updated version of the IP
Chapter of the proposed TPP. 9 3 The updated text revealed new proposals and
issues of interest. The deep resistance to the U.S.-backed measures that would
expand pharmaceutical monopoly power and compromise access to medicines
has endured for years. It became clear that "the U.S. has dropped some harmful
proposals, but continued to insist on many others." 94

&

IV. Overview of some of the U.S. proposals on patents
pharmaceuticals
A.

Patentability Requirements & Evergreening

Critics including public health experts, international organizations, government officials, academics, and civil society organizations have pointed out that
the patent provisions of the proposed IP chapter aim to lengthen, strengthen and
broaden patent protection, and thus the monopolies of pharmaceutical companies
in TPP negotiating countries. 95
Patent evergreening has been identified as a main area of concern for all of the
negotiating parties. Evergreening patents aim to extend the life of the original
patent through the patenting of minor changes in active pharmaceutical ingredients of existing products (polymorphs, salts, etc.), inert ingredients, formulations,
dosages, and combinations. 96
In terms of evergreening concerns, much attention has been paid to USTR's
text tabled in September 2011, which is widely known as the 'pharmaceuticals'
text. Nevertheless, a very significant threat lies in the heart of the U.S. February
2011 text. Article 8 of the IP chapter sets substantive standards for patent protec92 Burcu Kilic & Peter Maybarduk, What's New in the WikiLeaks TPP Text?, Punic CrrizEN's
GLOBAL Access To MEoIcINEs PROGRAM (November

13, 2013), http://www.citizen.org/documents/

Whats%20New%20in%20the%2OWikiLeaks%20TPP%2OText-

Ill.pdf.

93 See generally Trans-Pacific Partnership, Intellectual Property Rights Chapter, proposed May 2014,
available at https:/wikileaks.org/tpp-ip2/tpp-ip2-chapter.pdf.
94 Burcu Kilic & Peter Maybarduk, What's New in the 2014 WikiLeaks TPP Intellectual Property
Text? Pharmaceuticals:Landing Zones and Issuesfor MinisterialDiscussion, PuI1uc CrIzEN's GLOBAL
Accuss To MEDICINEs PROGRAM (October 16, 2014), http://www.citizen.org/documents/pharmaceuticals

-landing-zones-and-issues-for-ministerial.pdf.
95 See generally How the TPP EndangersAccess to Affordable Medicines, PunuC CITIZEN's GLOBAL
AccESS TO MEDICINES PROGRAM (November 2013), http://www.citizen.org/documents/TPPonepagerfinal
november2013.pdf (discussing longstanding concerns associated with U.S. draft proposal for the
Intellectual Property Chapter of the TPP).
96 Burcu Kilic & Luigi Palombi, The Question of Patent Eligible Subject Matter and Evergreening
Practices, INFOJUSTICE.ORG (July 27, 2013), http://infojustice.org/archives/30314#more-30314.
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tion. Articles 8.1,97 8.2,98 8.12,99 when read together, facilitate so-called evergreening patents.
The U.S. proposal provided U.S.-based patent protection extending the scope
of protection to new forms, uses, and methods of using a known product. Pharmaceutical companies would then be able to file patent applications for new
methods of preparation, new formulations and new uses of known substances
without being subject to any restrictions.
The only TPP countries - and the only countries in the world - to recognize
patent protection to diagnostic, therapeutic and surgical methods for the treatment of human beings are the U.S. and Australia." The exclusion of these methods from patentability is grounded in ethical values, i.e. to ensure physicians can
treat patients with therapies that best fit their needs. Patentability of new therapeutic applications of known drugs - known as second/subsequent use - also
falls within this exclusion. A new therapeutic application of a known drug is
widely considered a method for treatment of humans.' 0
Moreover, an introduction of patent protection for methods of treatment for
the human body in TPP countries without any safeguards could impose additional costs on their healthcare system. It is possible that hospitals could be required to obtain licenses for patented treatments that they offer, and doctors
could be asked to pay royalties for the patented diagnostic, therapeutic and surgical methods they use.
Article 8.1 of the February 2011 text provides patent protection to new uses
and method claims. Article 8.2 make methods of treatment for the human (or
animal) body eligible subject matter for patents. Article 8.12 interprets industrial
97 Article 8.1: The Parties confirm that patents shall be available for any new forms, uses, or methods
of using a known product; and a new form, use, or method of using a known product may satisfy the
criteria for patentability, even if such invention does not result in the enhancement of the known efficacy
of that product. FNI5: For the purposes of this Article, a party may treat the terms "inventive step" and
"capable of industrial application" as being synonymous with the terms "non-obvious" and "useful"
respectively. In determinations regarding inventive step (or non-obviousness), each Party shall consider
whether the claimed invention would have been obvious to a skilled artisan (or having ordinary skill in
the art) at the priority date of claimed invention. Trans-Pacific Partnership, Intellectual Property Rights
Chapter (Selected Provisions) art. 8.1 & n. 15, proposed September 2011, available at http://www.citizens
trade.org/ctc/wp-content/uploads/201 I/I0/TransPacificlPl.pdf.
98 Article 8.2: Each Party shall make patents available for inventions for the following: (a) plants and
animals, and (b) diagnostic, therapeutic, and surgical methods for the treatment of humans and animals.
Trans-Pacific Partnership, Intellectual Property Rights Chapter (Selected Provisions) art. 8.2, proposed
September 2011, available at http://www.citizenstrade.org/ctc/wp-content/uploads/20 I/I10/TransPacific
IPI.pdf.
99 Article 8.12: Each Party shall provide that a claimed invention is industrially applicable if it has a
specific, substantial, and credible utility. Trans-Pacific Partnership, Intellectual Property Rights Chapter
(Selected Provisions) art. 8.12, proposed September 2011, available at http://www.citizenstrade.org/ctc/
wp-content/uploads/201 1/10/TransPacificlPl.pdf.

100 Burcu Kilic & Tiffany Jang, Medical Procedure Patents in the TPP: A Comparative Perspective
on the Highly Unpopular U.S. Proposal, PuneIC CITIzEN's GLOBAL Accuss ro MEDICINES PROGRAM 2

(November 13, 2013), http://www.citizen.org/documents/MEDICAL%20PROCEDURE%20PATENTS
%201N%20THE%20TPP.pdf.
101 Ylsuke Sat6 & Jiameng Kathy Liu, Patent Protection of Medical Methods -Focusing on Ethical

Issues, 20 PAC. Rim. L. Poy. J. 125, 126 (2011) (discussing "therapeutic methods and their inclusion of
methods for treating humans using medical products such as medications").
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application in a broad sense and seeks specific, substantial and credible utility to
satisfy industrial application requirements. When read together, these three Articles assure patent eligibility for second or subsequent use of known products and
further restrict generic competition. Patenting of new forms, uses or methods of
known products would give rise to patents on minor variations of existing chemical entities, regardless of their impact on therapeutic efficacy, and risk greatly
expanding pharmaceutical patenting and restricting affordable access to
medicines.
The Wikileaks text of November 2013 revealed that the U.S. has dropped patents for "new forms" of known substances from its original proposal. 0 2 This
could be interpreted as a positive change. However, USTR still aims to impose
patents for new uses or methods of using old medicines, which can still facilitate
patent evergreening. Nine countries, including Canada, Singapore and New Zealand, oppose this proposal.' 0 3
According to updated version of the WikiLeaks text dated October 2014, the
U.S., Australia, and Japan still seek patent protection for new uses or new methods of using a known product.1 0 4 The language of this provision, however, has
been changed and arguably improved since November 2013. Negotiators
changed the language from "patents shall be available," to "Parties confirm that
patents are available." The Canadian proposal on "any new use . . . that is not
otherwise excluded from patentability by the Party" 0 5 is also new. This may
provide some additional flexibility for countries seeking to maintain their existing rules and practices. '0 6According to the Wikileaks text of November 2013,
the U.S. and Japan also propose a provision attacking Section 3(d) of the Indian
Patent Act, 0 7 a famous rule that has helped protect access to affordable
medicines worldwide. While the U.S. proposal against a limited efficacy requirement was included in earlier versions of the TPP text,' 0 8 it has been revised here
102 Trans-Pacific Partnership, Intellectual Property Rights Chapter art. QQ.E.1, proposed August
2013, available at https://wikileaks.org/tpp/static/pdf/Wikileaks-secret-TPP-treaty-IP-chapter.pdf.
103 Id.
104 Trans-Pacific Partnership, Intellectual Property Rights Chapter art. QQ.E. 1.4, proposed May 2014,
available at https://wikileaks.org/tpp-ip2/tpp-ip2-chapter.pdf ("US/AU/JP propose; CL/MY/PE/SG/VN/
BNINZ/CA/MX oppose: Consistent with paragraph 1, the Parties confirm that patents are available for:
(a) any new uses, or alternatively, new methods of using a known product").
105 Id. ("CA propose: Alt (a) any new use, or new method of using a known product that is not
otherwise excluded from patentability by the Party"). Id.
106 Burcu Kilic & Peter Maybarduk, What's New in the 2014 WikiLeaks TPP Intellectual Property
Text? Highlights of Section E: Patents / Undisclosed Test or Other Data, PunuIc CIrIZEN's GLOBAL
AccESs TO MEDICINES PROGRAM (October 16, 2014), http://www.citizen.org/DOCUMENTS/HIGH
LIGHTS-OF-SECTION-E.PDF.
107 The Indian Patent Act, Sec. (d), "the mere discovery of a new form of a known substance which
does not result in the enhancement of the known efficacy of that substance or the mere discovery of any
new property or new use for a known substance or of the mere use of a known process, machine or
apparatus unless such known process results in a new product or employs at least one new reactant." Sec.
3 (d), The India Patent Act, No. 39 of 1970, INDIA Coo (1995).
1os See generally Trans-Pacific Strategic Economic Partnership, Intellectual Property Rights Chapter
(Selected Provisions), proposed February 2011, available at http://keionline.org/sites/default/files/tpp- 10
feb2011 -us-text-ipr-chapter.pdf.
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to reflect USTR's position that 3(d) is an impermissible "fourth criterion" for
patentability. Even though India is not among the countries negotiating the TPP,
the U.S. has complained about India's patent rules and practices, and this TPP
provision is a clear effort to curb India's influence and the spread of the rule.
Under Section 3(d), a new form of a known chemical substance is not considered an invention if it "does not result in the enhancement of the known efficacy
of that [known] substance." However, a derivative of a known substance can
overcome this presumption against subject matter eligibility if it demonstrates a
significant difference in its properties with regard to efficacy.1 09
According to USTR, India's law creates a special, additional patentability criterion for select technologies like pharmaceuticals, which might be prohibited by
the TRIPS Agreement. Yet Section 3(d) is structured as a subject matter eligibility threshold, not as a patentability test.1 10 TRIPS provides WTO Members with
a flexibly to define what qualifies as an invention (patent eligible subject matter).
Like the U.S.,"' India excludes certain categories from patent eligible subject
matter.
In the second WikiLeaks text of October 2014, the first part of the provision
on new uses or methods of using a known product has been moved below as a
separate section. In the prior version, this provision had been tied to language on
new uses or methods of using known products. Two concepts have now been
separated.1 12
The November 2013 WikiLeaks text also revealed that after years of negotiations, USTR still seeks to impose medical procedure patents on Asian and Latin
American countries." 3 All eleven other negotiating countries oppose the proposal.11 4 Medical procedure patents raise healthcare costs. Health providers, including surgeons, could be liable for the methods they use to treat patients.
The U.S. has added the provision that medical procedure patents should be
available only "if they cover a method of using a machine, manufacture or composition matter."' 15 In one sense, this is progress, a modest limitation on a bad
rule. However, the proposed rule still fails to include safeguards in U.S. law that
immunize medical practitioners from suit, particularly when the machine, manufacture or composition of matter itself is not patented.
109 Kilic & Palombi, supra note 96.
110 India's Patent System Plays by WTO Rules and Supports Global Health, PuBIc CrriziN's
GLOBAL AccEss TO MEDICINES PROGRAM (Jun. 27, 2013), http://www.citizen.org/documents/Whats%20

New%20in%20the%2OWikiLeaks%20TPP%20Text- II.pdf.
Ill See generally Ass'n for Molecular Pathology et al. v. Myriad Genetics, Inc., et al., No. 12-398
(U.S. Jun. 13, 2013) (holding that "cDNA and isolated but otherwise unmodified DNA are patenteligible").
112 PUBUC CITIZEN'S GLOBAL AccESS TO MEDICINES PROGRAM, supra note 106.
113 Trans-Pacific Partnership, Intellectual Property Rights Chapter art. QQ.E.2, proposed August
2013, available at https://wikileaks.org/tpp/static/pdflWikileaks-secret-TPP-treaty-IP-chapter.pdf.
114 Trans-Pacific Partnership, Intellectual Property Rights Chapter art. QQ.E.1, proposed August
2013, available at https://wikileaks.org/tpp/static/pdf/Wikileaks-secret-TPP-treaty-lP-chapter.pdf.
115

Id.
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Essentially, except for when a surgeon uses her bare hands, surgical methods
would be patentable under the U.S. proposal. While U.S. law immunizes certain
care providers from infringement liability, the U.S. TPP proposal fails to include
these safeguards, risking more serious consequences for TPP negotiating
countries.'16
The rule flouts international norms. Eighty countries have excluded such
methods from patentability, only one other country permits them (Australia,
which nevertheless opposes the U.S. proposal), and medical societies worldwide
are outraged by the idea.' 1 7 Numerous FTA provisions reinforce TRIPS Articles
27.2 and 27.3, which expressly permit members to exclude from patentability
"diagnostic, therapeutic and surgical methods for the treatment of humans or
animals."' 8
On the other hand, the competing five-country proposal offers language similar to TRIPS Article 27.3119 affirming TPP countries' rights to determine whether
to include diagnostic, therapeutic, and surgical methods for treating humans and
animals as exceptions to patentability.
One very significant development in the new WikiLeaks text of October 2014
is the removal of the highly unpopular U.S. proposal on diagnostic, therapeutic,
and surgical methods patents, also known as medical procedure patents. Every
negotiating country aside from the U.S. opposed this proposal. Footnote 56 explains that the U.S. and Japan are "reconsidering the inclusion" of this proposal
subject to consensus in the patent landing zone.1 2 0 This is interpreted as a reference to a deal between Parties on patents for new uses/new methods of use in
exchange for the revocation of proposals on medical procedures.121
Patent Oppositions

B.

Pre-grant opposition is an important safeguard against patent abuse, improvidently granted patents and unwarranted pharmaceutical monopolies based on
weak or erroneous information.1 22 It helps improve patent quality and the efficiency of patent examinations by facilitating broad participation of the public and
private sector. Under an adversarial administrative process, any person, including
researchers, public interest groups and competitors are able to oppose a patent
application by submitting information and analysis to patent examiners.
116 Kilic & Jang, supra note 100, at 5.
117 Id. at 1.

118 Agreement on Trade-Related Aspects of Intellectual Property Rights art. 27.3, Apr. 15, 1994, 1867
U.N.T.S. 154.
119 Id.

120 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93, at n. 56 ("Negotiator's Note: US/JP reconsidering the inclusion of subparagraph (b) (provision relating to diagnostic, therapeutic and surgical methods), subject to consensus on patent landing zone. Trans-Pacific Partnership,
Intellectual Property Rights Chapter").
121 Kilic & Maybarduk, supra note 106, at 2.
122 See generally Pre-GrantOpposition, PunLuc CrriziN, http://www.citizen.org/documents/LeakedUS-TPPA-paper-on-eliminating-pre-grant-opposition.pdf (outlining the U.S. argument for eliminating
pre-grant opposition).
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Pre-grant opposition supports appropriate generic competition and access to
affordable medicines. The February 2011 text includes a provision eliminating
pre-grant opposition in TPP counties.1 23
The absence of pre-grant opposition would make patent examination less informed and would likely increase the number of post-grant cases before the
courts. Costs associated with the patent opposition system could rise significantly. This would create market uncertainty for generics firms, and lead to lowquality patents and unjustified drug monopolies until post-grant challenges could
reach a successful conclusion.1 24
According to the WikiLeaks text of November 2013, the U.S. has withdrawn
its highly controversial proposal to eliminate pre-grant opposition, a key mechanism used in TPP countries and many others to prevent patent abuse. A paper on
this U.S. proposal1 2 5 that was leaked in 2011 has been subject to significant international criticism.1 2 6 The five-country proposal explicitly requires countries to
provide a procedure for third persons to formally oppose the grant of a patent, but
leaves it to their discretion whether it should be before or after a decision on the
application or available at any time.1 2 7 This is a superior, pro-health alternative to
the original U.S. proposal.
The new WikiLeaks text of October 2014 revealed that the U.S. has withdrawn its highly controversial proposal to eliminate pre-grant opposition, a key
mechanism used in TPP countries and many others to prevent patent abuse. A
footnote referencing the proposal in last year's text has been removed.1 28 This
can be seen as a modest but important victory for public health policies.
C.

Patent Term Adjustments (for patent prosecution periods)

Patent term adjustments (typically called extensions) allow patent owners to
postpone patent expiry. This further delays market entry of competing generic
drugs and restricts access to affordable medicines.
The U.S. TPP proposal introduces general patent term adjustments applying to
all fields of technology including pharmaceutical products and processes. 2 9 The
U.S. proposal defines unreasonable delay as more than four years from the date
of filing or two years after an examination request.1 30
123 Trans-Pacific Strategic Economic Partnership, Intellectual Property Rights Chapter (Selected Provisions), supra note 108, at art. 8.7.
124 PUBLIC CIffZEN, supra note 122.
125 Id.

126 Risks of the Trans-PacificFree Trade Agreement for Access to Medicines: Analysis of the Leaked
U.S. Paper on Eliminating Patent Pre-Grant Opposition, PunIuc CrIzN (Jul. 7, 2011), http://www.
citizen.org/documents/analysis-of-leaked-US-paper-on-eliminating-pregrant-opposition.pdf.
127 Trans-Pacific Strategic Economic Partnership, Intellectual Property Rights Chapter (Selected Provisions), supra note 108, at art. 8.7.
128 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91, at art. QQ.E.4.
129 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91, at art. QQ.E.XX.
130

Id.
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Patent term adjustments not only allow patent owners to postpone patent expiry but they increase regulatory uncertainty and place an unnecessary burden on
patent offices. In the U.S., for instance, the United States Patent and Trademark
Office's (USPTO) laws and rules defining patent term adjustment are considered
"among the most complicated in patent practice."' 3 ' The section on patent term
extensions alone in the USPTO's Manual of Patent Examining Procedure
(MPEP) is nearly 50-pages long.1 32 This creates extra burden for the USPTO,
which struggles to keep-up with the ever-growing backlog of patent
applications.1 3 3
A patent term adjustment that is applicable to pharmaceutical products and
processes would further delay market entry of competing generic drugs, restricting access to affordable medicines.
The five-country counterproposal does not require patent term adjustments for
patent office delays per se. However, it explicitly addresses patent quality and
efficiency by encouraging Parties to improve quality and efficiency of their patent system, enhance their patent registration systems, simplify and streamline
administration systems for the benefit of all users of the system and the public as
a whole.1 34
This approach is more flexible and less burdensome for patent systems, yet
still creates unreasonable delays in processing of patent applications by encouraging Parties to address those delays. '5 It establishes a balance between the need
for flexibility to construct a patent system, which balances diverse private and
public interests.
The relevant provision in the October 2014 WikiLeaks text provided two options for countries. The Parties may either adjust the patent term or provide
136
means to adjust the term.
Option 2 provides more flexibility to countries. Even in the U.S., patent term
adjustment time is calculated using a complex set of rules that, in general, involves adding up the days of delay attributable to the patent office and then
137
subtracting the days of delays that the patent applicant himself caused.
131 Scott E. Kamholz, Patent Term Adjustment for Fun and Profit, INTELLECTUAL PROPERTY TODAY

(Aug. 24, 2006), http://patentlyo.com/medialdocs/2006/10/PTA_20for_2OFun_20and_2OProfit.pdf.
132 See generally MPEP § 2700 (8th ed. Rev. 2, May 2004).
133 See generally U.S. Gov'r ACCOUNTABIILTrY OiFie, GAO-07-1102, HIRING EPWoRus ARE NoT
SUFICIENT TO REDUCE THE PATENr APPLICATION BACKLOG (2007) (describing the patent application

backlog and its burden on the U.S. Patent and Trademark Office).
134 Trans-Pacific Strategic Economic Partnership, Intellectual Property Rights Chapter (Selected Provisions), supra note 108, at art. QQ.E.XX.2.
135 Trans-Pacific Strategic Economic Partnership, Intellectual Property Rights Chapter (Selected Provisions), supra note 108, at art. QQ.E.XX.2.
136 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91, at art. QQ.E.12
("US/SG propose78; CA/NZ/MY/VN/CL/PE/MX/AU/BN oppose:
{Option 1: Each Party, at the request of the patent owner, shall adjust the term of a patent to

compensate for unreasonable delays that occur in the granting of the patent.} (Option 2: If there
are unreasonable delays in a Party's issuance of patents, that Party shall provide the means to,

and at the request of the patent owner, shall, adjust the term of the patent to compensate for such
delays}").
137 Kamholz, supra note 131.
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Another conflicting issue is how to define unreasonable delays. The initial
U.S. proposal defined an unreasonable delay as the later of four years from the
date of filing or two years after an examination request. In alignment with their
prior FTA commitments, Chile and Peru proposed the later of five years from the
date of filing and three years after the examination request. Japan supports the
three-year proposal. 1 3 8
Subtraction of delays attributable to actions of the patent applicant is another
area where Parties have two options from which to choose. Option I allows Parties to subtract periods attributable to actions of the patent applicant from the
calculation of patent term extension. On the other hand, Option 2 allows Parties
to subtract not only periods attributable to actions of the patent applicant but also
the time taken to consider a third party's pre-grant patent opposition. 1 3 9
The U.S. has withdrawn its highly controversial proposal to eliminate pregrant opposition, a key mechanism used in TPP countries and many others to
prevent patent abuse. The TPP is no longer prescriptive on the matter; it is up to
Parties to decide what is best for their interests. Option 2 would allow authorities
to subtract from the calculation of a patent term extension the time taken to consider a third party's pre-grant patent opposition. For countries offering a pregrant opposition system, Option 2 seems to be more beneficial, as time taken to
consider the opposition would not extend the monopoly period in the event that
such an opposition was unsuccessful. An absence of this flexibility might have
implications for effective operation of pre-grant opposition systems in countries
that allow them.
According to footnote 81, the U.S. & Japan will work on an appropriate transition period for Parties who don't currently provide such a system for patent term
extensions. 14 0
V.

Pharmaceutical Patent Provisions

A.

Patent Term Adjustments (for regulatory approval periods)

During the TRIPS negotiations, the U.S. and EU proposed longer patent terms
for certain products like pharmaceuticals, which are subject to regulatory ap-

/

138 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91, at art. QQ.E.12
("For purposes of this {subparagraphlArticle}, an unreasonable delay at least shall include a delay in the
issuance of {the} / {a} patent of more than four [CL/PE propose: five] years from the date of filing of the
application in the territory of the Party, or two [JP/CL/PE propose: three] years after a request for examination of the application has been made, whichever is later").
139 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91, at art. QQ.E.12
("{Option 1: Periods attributable to actions of the patent applicant [JP propose: and to judicial or quasijudicial actions on the patent application] need not to be included in the determination of such delays.}
{Option 2: For the purposes of this Article, any delays that occur in the issuance of a patent due to
periods attributable to actions of the patent applicant or any opposing third person need not to be included in the determination of such delay}").
140 Id. at n.81 ("FN 81 Negotiator's Note: JP and US to lead work on an appropriate transition period
for Parties who do not currently provide such a system").
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proval. The negotiating parties rejected this proposal. 14 1 There are no extensions
of patent terms in TRIPS. Hence, TRIPS members are not obliged to offer longer
terms of protection for certain regulated products like pharmaceuticals.
The U.S. September 2011 proposal requires Parties make patent term extensions available for perceived delays in the regulatory approval process.1 4 2 It introduces patent term adjustments not only for patents covering new
pharmaceutical products but also for patents that cover methods of making or
using pharmaceutical products (this should be read in conjunction with Article
8.1, which makes patent protection available for new uses, methods and forms of
known products).1 4 3
The provision provides some flexibility for determining limitations on the period of patent term extensions. These limitations are similar to, though not entirely the same as, those found in the U.S. Patent Act,"4 i.e., a party may limit
extensions to one per pharmaceutical product.1 45
This widely criticized U.S. proposal would delay market entry of generic
drugs, thereby restricting access to affordable medicines. The WikiLeaks text of
November 2013 revealed that ten countries have announced their opposition.1 4 6
Notwithstanding, the five-country proposal addressed the issue under the title
of "processing efficiency" by encouraging countries "to process applications for
patents, and applications for marketing, regulatory or sanitary approval of pharmaceutical products, in an efficient and timely manner." 47 In the case of delays,
the parties "shall endeavour" to address those delays.1 48 Under the endeavours
standard, the Parties are expected to act to their own detriment considering the
standards of reasonableness, which can advance traditional public health goals
while addressing accountability and efficiency.
The scope of the provision is narrower than the WikiLeaks text regarding
which pharmaceutical patents would be subject to a patent term adjustment. It
does not apply to patents covering methods of making or using pharmaceutical

141 UNCTAD-ICTSD, RESOURCE BOOK ON TRIPS AND DEVELOPMENT 422-426 ( Cambridge Univ. Press 2004), available at http://www.iprsonline.org/unctadictsd/docs/RB2.5_Patents_2.5.6
update.pdf.
142 Trans-Pacific Partnership, Intellectual Property Rights Chapter (Sept. 2011), available at http://
www.citizenstrade.org/ctc/wp-content/uploads/201 I1/0/TransPacificiPI.pdf.

143 Id.
144 Extension of Patent Term, 35 U.S.C. §156 (2011).
145 See 35
146

U.S.C §156 (c).

Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E.14.

147 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E.X.X.3.
148 Id.
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products.1 4 9 This is an important development in the sense that it is more limited
than the relevant provision in the Korea-US Free Trade agreement.1 5 0
Differently from the previous WikiLeaks text of November 2013, the current
version of the text does not prescribe limitations, but rather allows Parties to
provide for conditions and limitations within their own legal system and
practice.'
B. Data Exclusivity (Submission of Information or Evidence Concerning the
Safety or Efficacy of a New Pharmaceutical Product)
Article 39.3 of TRIPS covers the "protection of undisclosed information",
which relates broadly to what are generally known as "trade secrets".1 5 2 It does
not require "data exclusivity," which prevents regulators from relying on a pharmaceutical company's data to evaluate competing products.' 5 3 Instead, Article 39
only requires protection of undisclosed test data on new chemical entities, the
collection of which involved considerable effort, against disclosure unless steps
are taken to ensure that the data is protected against "unfair commercial use."
The North American Free Trade Agreement (NAFTA) includes a similar passage, but also specifically prevents regulators from relying on an originator's data
for a reasonable period.1 54 The U.S. sought a provision in TRIPS based on this
NAFTA paragraph.15 5 This proposed provision was excised from the TRIPS
Dunkel Draft in 1991 and was never restored to the TRIPS Final Act of 1994.156
The TRIPS drafters' refusal to adopt the NAFTA provision is one of several
factors demonstrating their intention to provide for data protection, not data exclusivity, in TRIPS.
On the other hand, data exclusivity prevents regulatory authorities from relying on established data regarding drug safety and efficacy in order to register
149 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E. 14 ("l.
Each Party shall make best efforts to process patent applications and applications for marketing approval218 of pharmaceutical products in an efficient and timely manner, with a view to avoiding unreasonable or unnecessary delays. 2. With respect to a pharmaceutical product that is subject to a patent,
each Party shall make available an adjustment219 of the patent term to compensate the patent owner for
unreasonable curtailment of the effective patent term as a result of the marketing approval process. 3. For
greater certainty, further to/consistent with Article QQ.A.5.220, each Party may provide for conditions
and limitations in implementing the obligations of this paragraph").
150 See United States-Korea Free Trade Agreement art. 18.8.6.(b), June 30, 2007, available at http://
www.ustr.gov/sites/default/files/uploads/agreements/ftalkorus/assetupload-file273
12717.pdf.
151 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93, at Art. QQ.E.14.3
("For greater certainty, further to/consistent with art. QQ.A.5220, each Party may provide for conditions
and limitations in implementing the obligations of this paragraph").
152 Agreement on Trade Related Aspects of Intellectual Property Rights art.39.3 Apr. 15, 1994, 1867
U.N.T.S. 154, available at http://www.wto.org/english/docs -ellegal-e/27-trips_04d e.htm#7.
153 Data exclusivity in international trade agreements: What consequences for access to medicines?

(MSF technical brief May 2004), http://www.citizen.org/documents/dataexclusivitymay04.pdf.
154 North American Free Trade Agreement, U.S.-Can.-Mex., art.1711.5, Dec. 8, 1993, 32, I.L.M. 289
(1993) [hereinafter NAFTA].
155 NAFTA, supra note 154, art 1711.5-6.
156 CORREA, supra note 31 at 385-87.
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generic medicines. It creates patent-like monopolies over the test data by preventing generic manufacturers from relying on the original data. Apart from duplicating costly and time-consuming clinical trials, the generic manufacturers are left
with no other option but to wait. Thus, data exclusivity delays generic market
entry and is inconsistent with medical ethical standards against duplicating tests
on humans or vertebrate animals.
The September 2011 text requires data exclusivity for new pharmaceutical
products.' 57 This provision provides "at least five years" of data exclusivity for
safety and efficacy information submitted in support of marketing approval, even
if it is disclosed and in the public domain.'1 5 The text also introduces "at least
three years" additional data exclusivity for submission of new clinical information on new uses or indications for existing pharmaceutical products.' 59 Products
that are considered the same as or similar to the reference product are also prevented from relying on its protected data.
By introducing automatic data exclusivity protection for new pharmaceutical
products and new clinical information, the U.S. proposal limits countries' abilities to define TRIPS compliant flexible rules for test data protection and challenges the efforts of countries to safeguard access to medicines.
According to the WikiLeaks text of November 2013, the U.S. is still insisting
on its proposal, which is more aggressive than data exclusivity provisions in prior
FTAs,' 60 even though eight other negotiating parties oppose it.161 In a footnote,
Canada "reserves its position," and Japan states that it is still considering its
position. 162
The new version of this provision in WikiLeaks text of October 2014 mirrors
the language in the Australia-U.S. Free Trade Agreement (AUSFTA). New version of the provision allows for "at leastfive years" of "data exclusivity" (technically this appears to be market exclusivity) for new pharmaceutical products, and
"at least three years" of data exclusivity for previously approved pharmaceutical
products containing a "new clinical information (other than information related to
bioequivalency)" or "evidence of prior approval of the product in another territory" running from the date of marketing approval for that product in the Party's
territory. 163
157 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E.16.
158 Id.
159 Id.
160 Comparative Table ofData Exclusivity Provisions in the U.S. Proposal to the Trans-Pacific Part-

nership Agreement, Punic CrnzEN (Sep. 2013), http://www.citizen.orgleaked-TPP-text-and-analysis2.
161 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E.16.
162 Id.

163 Id. ("Article QQ.E. 16: {Pharmaceutical Data Protection} (a) If a Party requires, as a condition for
granting marketing approval for a new pharmaceutical product, the submission of undisclosed test or
other data concerning the safety or efficacy of the product, the Party shall not permit third persons,
without the consent of the person who previously submitted such information, to market the same [MY
oppose: or a similar221] product on the basis of: i. that information; or ii. the marketing approval granted
to the person who submitted such information for at least five years from the date of marketing approval
of the new pharmaceutical product in the territory of the Party [MY propose:, or any other country where
marketing approval is first granted"). Id.
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Distinct from the WikiLeaks text of November 2013, the provision distinguishes between the information required and permitted. If a Party requires the
submission of an undisclosed test or other data prior to granting marketing approval, paragraph (a) applies. If a Party relies on the marketing approval conferred in a foreign country, paragraph (b) applies. M
The scope of exclusivity is more limited now; data exclusivity is only provided for "undisclosed test or other data."1 65
Products that are considered to be the same as or similar to their reference
product cannot rely on the reference product's protected data. Footnote 221 clarifies that a pharmaceutical product can be "similar" to a previously approved
pharmaceutical product if the marketing approval of that similar pharmaceutical
product is based upon the information concerning the safety or efficacy of the
previously approved pharmaceutical product, or the prior approval of the reference product. Malaysia is the only country opposing the application of data exclusivity for similar products.1 66
Footnote 222 allows Parties to retain their current system if they provide data
exclusivity for previously approved pharmaceutical products containing "new
clinical information (other than information related to bioequivalency)" or "evidence of prior approval of the product in another territory" on the date of entry
into force of this Agreement. The footnote further clarifies that additional data
exclusivity protection on the submission of new chemical information does not
extend to biologics and/or pharmaceutical products that receive eight years of
data exclusivity167 (as in the case of Japan 1 68). The provision also includes safe164 Id. ("Article QQ.E. 16 (b) If a Party permits, as condition of granting marketing approval for a new
pharmaceutical product, the submission of evidence of prior marketing approval of the product in another
territory, the Party shall not permit third persons, without the consent of a person who previously submitted such information concerning the safety or efficacy of the product, to market a same [MY oppose: or a
similar] product based on evidence relating to prior marketing approval in the other territory for at least
five years from the date of marketing approval of the new pharmaceutical product in the territory of the
Party [MY propose:, or any other country where marketing approval is first granted].
[CL propose: Alt (b) A Party may provide for the possibility of granting marketing approval or
sanitary permit for a new pharmaceutical product based on a prior marketing approval in another territory. If a Party provides for such possibility, it may also require consent or acquiescence of a person
previously submitting the undisclosed test or other data to obtain marketing approval in the other territory
in order to authorize a third person to market a same or similar product (in the territory of the Party) for at
least 5 years from the date of the first/prior marketing approval of the new pharmaceutical product.]"). Id.
165 Id. at QQ.E.XX.4. ("[T]he submission of undisclosed test or other data concerning the safety or
efficacy of the product.")
166 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93, at n. 221 ("For
greater certainty, for purposes of this Section, a pharmaceutical product is "similar" to a previously
approved pharmaceutical product if the marketing approval of that similar pharmaceutical products is
based upon the information concerning the safety or efficacy of the previously approved pharmaceutical
product, or the prior approval of that previously approved product.").
167 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93, at n. 222 ("As an
alternative to this paragraph, where a Party, on the date of entry into force of this Agreement for that
Party, has in place a system for protecting information submitted in connection with the approval of a
pharmaceutical product that utilizes a previously approved {AU/NZ/SG oppose: chemical) {AU/NZ/SG
propose: activel component from unfair commercial use, the Party may retain that system, notwithstanding the obligations of this paragraph. Additionally, a Party is not required to apply Article QQ.E.16.2
with respect to pharmaceutical products covered by Article QQ.E.20 [CA oppose: or to pharmaceutical
products that receive a period of at least 8 years of protection pursuant to subparagraph 1(a) and 1(b) of
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guards for Parties to take measures to protect public health in accordance with
the TRIPS Agreement and Doha Declaration. These safeguards are new, and they
are borrowed from the previous FTAs (Peru US FTA, Korea-US FTA).1 69 Malaysia proposes a provision which adds clarity and certainty to the public health
safeguards mentioned above: it includes a flexible clause that would enable Parties to waive data exclusivity for the protection of public health, non-commercial
public use, national emergency, or other urgent circumstances as determined by
the party.1 70

'

Malaysia also proposes the creation of a window within which a pharmaceutical company should file a marketing approval request after the data on the product is first registered. This so-called 'access window' is eighteen months for
pharmaceutical products and twelve months for previously approved pharmaceutical products.' 7
C.

Exclusivity on Biologics

Since the beginning of the TPP negotiations, the pharmaceutical and biotech
industries have been demanding a special 12-year exclusivityl 72 period for bioArticle QQ.E.16.][CA propose: A Party that provides a period of at least 8 years of protection pursuant to
QQ.E.16.1 is not required to apply Article QQ.E.16.2.]").
168 There is no data exclusivity in Japan. Nevertheless, the Japanese Post Marketing Surveillance
(PMS) system, which aims to monitor and confirm the efficacy and safety of approved new drugs, provides de facto exclusivity to pharmaceutical companies against generic entry, even in some cases after
patent expiration. A re-examination period is set for most new drug approvals, and until this period is
over, generics companies cannot submit their applications for drug approvals. It does not provide for
exclusive use of the data, however in practice it delays the market entry of generic drugs. The re-examination period is 8 years from the date of marketing approval for active ingredients and 4-6 years from the
date of marketing approval for new indications and doses. See Burcu Kilic, Mikyoeng Kim & Peter
Maybarduk Challenges for Health and Innovation Policy in the Trans-Pacific PartnershipAgreement
(TPP): ComparativeAnalysis of the United States' TPP Intellectual Property Proposaland the Japanese
Law, Puniuc CrnizN (Jan. 2014), http://www.citizen.org/documents/comparitive-table-japan-and-tppjanuary-2014.pdf.
169 The text of the safeguard reads: "Notwithstanding paragraphs I and 2 above, a Party may take
measures to protect public health in accordance with: (a) the Declaration on the TRIPS Agreement and
Public Health (WT/MIN(01)/DEC/2) (the "Declaration"); (b) any waiver of any provision of the TRIPS
Agreement granted by WTO Members in accordance with the WTO Agreement to implement the Declaration and in force between the Parties; and (c) any amendment of the TRIPS Agreement to implement
the Declaration that enters into force with respect to the Parties." Trans-Pacific Partnership, Intellectual
Property Rights Chapter, supra note 91 at art. QQ.E.16.2.
170 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93 at art. QQ.E.16.6
("[MY Propose: .. .(b) necessary to protect public health, national security, non-commercial public use,
national emergency or other urgent circumstances as determined by the Party.]").
171 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93 at art. QQ.E.16.5
("[MY propose: 5.A Party may for the purpose of granting protection under paragraph 2 require an
applicant to commence the process of obtaining marketing approval for that pharmaceutical product
within 12 months from the date the product is first registered or granted marketing approval, and granted
protection for such information in any country.]").
172 The Affordable Care Act requires 12 years of biologics exclusivity (4 years data and 8 years
market). But the White House aims to reduce this period to seven years, and has pledged to consumers
and federal programs the resultant savings in its recent annual budgets. Kilic & Maybarduk, supra note
92 at 9.
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logics. 17 3 Biologics, including many new cancer drugs, are exceptionally expensive and constitute one of the main drivers of rising healthcare costs.17 4 The U.S.
has included a placeholder for automatic monopolies on such biotech medicines
in its previous TPP proposals.17 5 In late November 2013, USTR reportedly proposed 12 years of data exclusivity for biologics as a part of a non-paper proposing temporary differential treatment for low-income TPP countries on three key
pharmaceutical IP protections. 17 6
Imposing biologics exclusivity would constitute a major change to countries'
laws with potentially dramatic financial consequences for patients, medical providers, and governments.
On the other hand, half of the TPP countries have advanced an alternative,
superior vision to the U.S. data exclusivity proposal. 177 This provision mirrors
the language of TRIPS Article 39.3 on the protection of undisclosed information,
78
and comes without imposing the burden of pharmaceutical monopolies.s
Furthermore, Paragraph 3 of the proposal explicitly recognizes the Doha Declaration
and any waiver or amendment of the TRIPS Agreement. 7 9
The October 2014 WikiLeaks text includes a new provision that provides exclusivity for biologics. The provision makes direct reference to Article QQ.E.16
on exclusivity.1 s0 There are two issues where Parties have disagreements: the
period of protection and the definition of biologics.""s The period of protection
173 12 Years of Data Protection in TPP, PhRMA, http://www.phrma.org/note-media-elected-officialssupport-I 2-years-data-protection-tpp.
174 Kilic & Maybarduk, supra note 92 at 9.
175 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E.16.
176 In TPP, U.S. Floats 12-Year Data Periodfor Biologics, Flexibilities for Developing Countries,
Inside U.S. Trade (Nov. 29, 2013), http://insideepa.com/index.php?option=com user&view=login&
retum=AHROcDovL21uc21kZWVwYS5jb2OvMjAxMzExMjcyNDUOMzA2L1dUTylEYWiseS1OZXdz
LORhaWx5LU5Id3MvaW4tdHBwLXVzLWZsb2FcyOxMiI 5ZWFyLWRhdGEtcGVyaW9kLWZvcilia
W9sb2dpY3MtZmxleGliaWxpdGllcylmb3ItZGV2ZWxvcGluZyljb3VudHJpZXMvbWVudSI pZCO5N
DguaHRtbA=FC.
177 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E.XX.4.
178 Id.
179 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E.XX.4.3
("Each Party may take measures to protect public health in accordance with: (a) the Declaration on the
TRIPS Agreement and Public Health (WT/MIN(01)/DEC/2) (the "Declaration . . . ").
180 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93 at art. QQ.E.20
("With respect to the first marketing approval of a pharmaceutical product that is biologic, 231 each Party
shall provide the protection afforded under Article QQ.E.16.1 (a)-(b), mutatis mutandis for a period of [0]
/ [5] / [8] / [12] years from the date of marketing approval of such pharmaceutical product in that Party.")
181 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93 at n. 231 ("Negotiator's Note: Delegations discussed two approaches to a footnote on biologics, which are set forth below.
Delegations had different views and preferences regarding these two approaches. Approach 1: {For purposes of this Chapter, a pharmaceutical product that is biological means [at least] a vaccine, a protein, or
a [AU propose: plasma-derived product, US propose: blood-derivative, JP propose: blood-derived product] for use in human beings for the prevention, treatment, or, cure of a disease or condition. A Party may
limit the scope of such pharmaceutical products to products that are produced [US propose: at least in
part, through biological processes involving living organisms, tissues, or cells, such as those involving]
[US oppose: by biotechnology [such as]/[including]] recombinant DNA technology. [CA propose: Products that] a Party may exclude [CA oppose: the following] from the scope of such pharmaceutical products, [CA: include: ] blood and blood components, chemically synthesized polypeptides, and [US
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ranges from zero years to twelve years including five and eight years.1 82 Most of
the TPP countries already provide five years exclusivity to biologics under their
data exclusivity regimes.1 83 That's why footnote 232 includes a grandfathering
clause. Countries in which biologics can already receive exclusivity under the
general data or marketing exclusivity rules have a five-year transitional period
before they must provide the TPP's special terms for biologics.1 8 4
The definition of "biologic" is yet another matter of controversy among Parties
because it will determine which products may receive the special and longer exclusivity periods under discussion in this Article. According to Footnote 231,185
the delegations discussed two approaches and have different views and preferences regarding these two approaches. Approach 2 is the better approach: it allows for self-definition and provides flexibility to each country to implement the
standards that work best for them. Biotechnology is a fast moving field; Parties
would like to have flexibility to update their definitions in the future.
VI.

Patent Linkage

Patent linkage is a regulatory mechanism that links drug marketing approval to
patent status. The system creates a second tier for patent monopoly and shifts the
burden of early patent enforcement to the regulatory authorities.' 86 Under patent
linkage, even spurious patents may function as barriers to generic drug registration. The TRIPS Agreement includes no requirement to provide a system for
patent linkage.
The U.S. September 2011 proposal requires countries to provide a mechanism
to identify patents covering an approved pharmaceutical product or its approved
method of use.1 87 This "linkage" provision is more aggressive than comparable
measures in past FTAs.' 88 The U.S. draft introduced a notification system for
patent holders, an automatic stay of marketing approval and measures to block
propose: naturally occurring] animal-derived polypeptides that are derived wholly by means of extraction
and purification from animal organs and tissues [CA propose: or from plants]} Note: Delegations also to
consider necessity and potential drafting of the following text: [CA oppose: For greater certainty, each
Party confirms that pharmaceutical products that are not defined as biologics under this provisions [are
subject to]/[shall be evaluated under] Article QQ.E.16.] Approach 2: Self-defining / according to national
law.").
182 Kilic & Maybarduk, supra note 94 at 1.
183 These countries include Australia, New Zealand, Chile, Singapore.
184 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93 at n. 232 ("Each
Party may provide that an applicant may request approval of a pharmaceutical product that is a biologic
under the procedures set forth in Article QQ.E.16 (1)(a)-(b) within 5 years of entry into force of this
Agreement, provided that other pharmaceutical products in the same class of products have been approved by the Party under the procedures set forth in Article QQ.E.16(l)(a)-(b) before entry into force of
this Agreement.").
185 See U.S. Floats 12-Year Data Periodfor Biologics, Inside U.S. Trade, supra note 176.
186 Benjamin P. Liu, Fighting Poison With Poison? The Chinese Experience With Pharmaceutical
Patent Linkage, II J. MARSHALL Riv. INTELL. PRo. L. 623, 627 (2012).
187 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E. 17.
188 Comparative Table of Patent Linkage Provisions in U.S. Free Trade Agreements and the U.S.

Proposalto the Trans-PacificPartnership(TPP) Agreement, Puniic CrrlZEN, Jun. 27, 2013, http://www.
citizen.org/documents/patentlinkagetablewclauses.pdf.
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allegedly infringing products for the duration of the patent.'5 9 The regulatory
authorities, lacking both the jurisdiction and competence to deal with issues relating to patent validity and relevance, get involved in the enforcement of pharmaceutical patents.
Patent linkage is a particular TRIPS-plus provision, which extends the patent
monopoly beyond the statutory term of twenty years.1 90 Under the linkage system, a generic manufacturer can only apply for the necessary regulatory approvals after the patent has expired. The time it takes a generic drug to enter into a
market varies but it usually takes a couple of years, which will result in de-facto
extension of the patent term. Thus, it can facilitate abuse since the financial benefits to patent holders of deterring generic market entry may outweigh risks of
penalties.
Interestingly, the Wikileaks text revealed that no comments seem to have been
recorded related to this measure. Patent linkage may be the most unpopular proposal in the text. 9 1 The counterproposal does not include any provision on patent

linkage.
The WikiLeaks text of October 2014 provides two options for the Parties. The
first option' 9 2 mirrors the language in the Australia-US FTA'9 3 creating a patent
189 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93, at Art. QQ.E. 14.3.
190 TRIPS: Agreement on Trade-Related Aspects of Intellectual Property Rights, art. 33, Apr. 15,
1994 WORLD TRADE ORGANIZATION, available at http://www.wto.org/english/tratop-e/trips-e/ltagm3c
e.htm#5 (Term of Protection: The term of protection available shall not end before the expiration of a
period of twenty years counted from the filing date.).
191 Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art. QQ.E.14.
192 Id. Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93 ("Article
QQ.E.17 (Patent Linkage): Where a Party permits, as a condition of approving the marketing of a pharmaceutical product, persons, other than the person originally submitting the safety or efficacy information, to rely on evidence or information concerning the safety or efficacy of a product that was previously
approved, such as evidence of prior marketing approval by the Party or in another territory:
(a) that Party shall provide measures in its marketing approval process to prevent those other
persons from:

i. marketing a product, where that product is claimed in a patent; or ii. marketing a product
for an approved use, where that approved use is claimed in a patent, during the term of
that patent, unless by consent or acquiescence of the patent owner FN224 [CA propose:

FN 225]; and (b) if the Party permits a third person to request marketing approval to enter
the market with: i. a product during the term of a patent identified as claiming the product;
or ii. a product for an approved use, during the term of a patent identified as claiming that
approved use, the Party shall provide for the patent owner to be notified of such request
and the identify of any such other person.").
193 Comparative Table of Patent Linkage Provisions in U.S. Free Trade Agreements and the U.S.
Proposal to the Trans-PacificPartnership(TPP) Agreement, supra note 188 (Art. 17.10.4. U.S.-Australia FTA (2005): "Where a Party permits, as a condition of approving the marketing of a pharmaceutical
product, persons, other than the person originally submitting the safety or efficacy information, to rely on
evidence or information concerning the safety or efficacy of a product that was previously approved,
such as evidence of prior marketing approval by the Party or in another territory: (a) that Party shall
provide measures in its marketing approval process to prevent those other persons from: (i) marketing a
product, where that product is claimed in a patent; or (ii) marketing a product for an approved use, where
that approved use is claimed in a patent, during the term of that patent, unless by consent or acquiescence
of the patent owner; and (b) if the Party permits a third person to request marketing approval to enter the
market with: (i) a product during the term of a patent identified as claiming the product; or (ii) a product
for an approved use, during the term of a patent identified as claiming that approved use, the Party shall
provide for the patent owner to be notified of such request and the identity of any such other . . . .").
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linkage mechanism. A Party is required to include measures in its regulatory
process to prevent the applicant from marketing a product, or a product for an
approved use, that is claimed under a patent. This obligation extends to cover the
entire term of the patent, unless the patent owner has consented to, or acquiesced
in, the use of the information.
If a Party chooses not to implement paragraph 1, a Party can provide a system
where marketing approval is linked to "consent or acquiescence" of a patentee.
This language mirrors the US-Chile FTAl 9 4 . Under this system, a Party shall not
grant marketing approval to any third Party prior to expiration of the patent term,
unless by "consent and acquiescence" of the patent owner. The identity of the
any third party requesting marketing approval will be available to the patent
owner during the term of the patent.1 9 5
Footnote 228 is a proposal by Chile, which allows Parties to use injunctions or
other judicial proceedings within their infringement proceedings.1 9 6
According to footnote 229, in the absence of legal action by a right holder (the
state of acquiescence) if a Party delays the issuance of marketing approval to a
third party until the expiration of the patent term, the Party is not required to
provide notification or make available the information about third parties applying for marketing approval.1 97
Footnote 230 clarifies that the patent linkage provision should not be interpreted so that marketing approval authority would be making validity or infringement determinations.1 98

194 Id. (Art. 17.10.2. U.S.-Chile FTA (2004): "With respect to pharmaceutical products that are subject to a patent, each Party shall: (. . .) (b) make available to the patent owner the identity of any third
party requesting marketing approval effective during the term of the patent; and (c) not grant marketing
approval to any third party prior to the expiration of the patent term, unless by consent or acquiescence of
the patent owner.") Id.
195 See Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93 at art.
QQ.E.17.2 ("Where a Party chooses not to implement paragraph 1, such Party shall provide that with
respect to any pharmaceutical product that is subject to a patent FN226 [MX propose: FN 227]: (a) the
Party shall not grant marketing approval to any third party prior to the expiration of the patent term,
unless by consent or with the acquiescence of the patent owner [CL propose: FN 228]; and (b) the Party
shall provide for the patent owner to be notified of, or make available to the patent owner, the identity of
any third party requesting marketing approval effective during the term of the patent.").
196 See Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 93 at art.
QQ.E.17.2.(a) ("Footnote 228 [CL propose: For greater certainty, Parties may comply with this obligation by providing for injunctions or other judicial proceedings within their patent infringement
procedures.]").
197 See Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art.
QQ.E.172.(b) ("Footnote 229 {For greater certainty, a Party is not required to provide the notification or
to make available the information set forth in paragraph 2(b), if that Party precludes the issuance of
marketing approval or sanitary permit to a third party prior to the expiration of the patent term in the
absence of legal enforcement action by a right holder.}").
198 See Trans-Pacific Partnership, Intellectual Property Rights Chapter, supra note 91 at art.
QQ.E. 172.(b) ("Footnote 230 For greater certainty, the Parties recognize that this Article does not imply
that the marketing approval authority should make patent validity or infringement determinations.").
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VH.

The landing zones

The IP provisions relating to pharmaceuticals and access to medicines are
likely some of the more controversial provisions in the TPP. The WikiLeaks text
revealed unanimous or nearly unanimous opposition from other countries to the
U.S. IP proposals, and indeed heroic efforts by some countries to advance the
public interest and public domain.1 99 Most importantly, there was a deadlock
over the IP Chapter, leading to an impasse in the TPP talks.
In order for the negotiations to advance, the U.S. needed to show more flexibility. Hence, U.S. negotiators developed a two-tier system that sets different
standards for developed countries and developing countries for pharmaceutical IP
provisions. 2 00 A non-paper tabled 2 0 1 in late November 2013, offered temporary
differential treatment for low-income TPP countries on three key pharmaceutical
IP provisions; patent term adjustment for regulatory delays, data exclusivity and
patent linkage. The proposal provides a transition period for some TPP parties
before they are required to implement much stronger intellectual property provisions on medicines and medical devices. 2 0 2
Reportedly, countries with per capita gross national income (GNI) under
$12,616203 would not have to apply the full set of tougher patent and data rules
until they cross that income threshold. 2 04 This would place Malaysia, Peru, Mexico, and Vietnam, below the threshold required for differential treatment. 205
However, only Vietnam would likely have many years before it must implement
the more restrictive rules.
The other TPP members, the U.S., Japan, Canada, Australia, Brunei, Chile,
New Zealand and Singapore, are identified as high-income countries by the
World Bank and would be subject to the standards based on language contained
in the Australia, Chile, and Singapore FTAs. 2 0 6
199 See generally Trans-Pacific Partnership, Intellectual Property Rights Chapter, proposed August
2013, available at https://wikileaks.org/tpp/static/pdf/Wikileaks-secret-TPP-treaty-IP-chapter.pdf.
200 In TPP, U.S. Floats 12-Year Data Period for Biologics, Flexibilitiesfor Developing Countries,

supra note 176.
201 A proposed agreement or negotiating text circulated informally among delegations for discussion
without committing the originating delegation's country to the contents. It has no identified source, title,
or attribution and no standing in the relationship involved. See, Aide-mdmoire http://en.wikipedia.org/
wiki/Aide-m%C3%A9moire.
202 In TPP, U.S. Floats 12- Year Data Periodfor Biologics, Flexibilitiesfor
Developing Countries,
supra note 176.
203 Based on 2012 GNI figures, countries with a per capita GNI of $12,616 or more are classified as
high income by the World Bank. New Country Classifications, World Bank, http://data.worldbank.org/
news/new-country-classifications.
204 In TPP, U.S. Floats 12-Year Data Period for Biologics, Flexibilitiesfor Developing Countries,

supra note 176.
205 See Country and Lending Groups, THE WoRil.

BANK,

http://data.worldbank.org/about/country-

and-lending-groups#Upper middleincome.
206 Stakeholder Input Sharpens, Focuses U.S. Work on PharmaceuticalIntellectual Property
Rights in
the Trans-PacificPartnership, Office of the United States Trade Representative (Nov. 29, 2013), http://

www.ustr.gov/about-us/press-office/blog/2013/November/stakeholder-input-sharpens-focuses-us-workon-pharmaceutical-IP-in-TPP.
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The Wikileaks text of October 2014 revealed that there is a second proposal
for transition periods. Addendum 11207 includes a proposal on patent
pharmaceuticals transition periods. This proposal would enable countries to delay, for defined periods of time, the implementation of certain aspects of the
intellectual property chapter based on a certain category classification. The text
does not reveal which country or countries authored the proposal, nor does it
show which countries support the proposal or which countries oppose it. The
grounds for placement of countries in one of the three categories in Addendum II
are not specified in the text. Category A includes the United States, Japan and
Singapore, with other countries to be confirmed. 2 08 Category B includes Mexico
and Brunei, with other countries to be confirmed. Category C includes only Peru
and Vietnam. Australia, Canada, Chile, Malaysia and New Zealand are not yet
categorized in the text. 2 0 9
As the negotiations progressed, the parties explored the option of developing
mutually acceptable packages for political decision making. The term 'landing
zones' emerged to describe remaining sensitive and challenging issues. The
landing zones identified pathways forward for matters related to market access,
financial services, and government procurement as well as the texts covering
intellectual property, competition, and environmental issues. 2 10
In July 2014, Inside U.S. Trade obtained a two-page document, outlining landing zones for resolving pharmaceutical IP issues 2 11. The document reflects the
current state-of-play of the discussion on pharmaceutical IP rules, which demonstrates that as of its writing there were still fundamental disagreement over these
provisions. 2 12
By way of illustration, 12-year exclusivity for biologics is a highly politicized
issue in the TPP negotiations. The landing zones paper illustrates that this U.S.
proposal received significant pushback from other countries, as the options under
consideration are zero years, five years and eight years. 2 13
Similarly, there are three other proposals for patent linkage provisions. The
first option is a hybrid based on three U.S.-FTAs (Singapore, Chile and Australia), which was likely proposed by the U.S. The second option limits the cover207 See generally Kneivel & Kilic, Addendum II Transition Periods Proposalfor Implementation of
Onerous Trans-Pacific Partnership Intellectual Property Rules, PuI31-c CrnzIN, October 2014 available
at http://www.citizen.org/documents/tpp-transition-periods.pdf.
208 Id.
209 Id.
210 Joint Press Statement TPP MinisterialMeeting Bandar Seri Begawan, Brunei Darussalam, Office

of the UnitedStates Trade Representative (Aug. 2013), http://www.ustr.gov/Joint-Press-Statement-TPPMinisterial-Brunei.
211 Leaked TPP Paper on Drug IP Landing Zones Shows Extent of Divisions, Inside U.S. Trade (Aug.
1, 2014), http://insidetrade.com/index.php?option=com-user&view=login&return=AHROcDovL21uc2lk
ZXRyYWRILmNvbS9JbnNpZGUtVVMtVHJhZGUvSW5zaWRILVUuUy4tVHJhZGUtMDgvMDEvMj
AxNC9sZWFrZWQtdHBwLXBhcGVyLW9uLWRydWctaXAtbGFuZGIuZyI 6b251cy I zaG93cy IleHRlb
nQtb2YtZGl2aXNpb25zL2 I IbnUtaWQtMTcyLmhObWw.
212 Id.
213 Id.
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age to only product patents. Last but not least, the third option makes patent
linkage completely optional for the countries.
For data exclusivity, the paper lays out six options ranging from a hybrid
model based on three U.S. FTAs to more flexible options limiting the scope and
application of data exclusivity to certain products.
VIII.

Conclusion

TRIPS sets the standards for IP protection in the world today, and is binding
on all Members of WTO. However, it includes certain flexibilities for Members
to implement the rules in a manner supportive of their own rights in order to
protect public health and access to medicines. It is far from perfect, but it provides some policy space for Members to address public health challenges.
However, there is little optimism about the future of this half-hearted IP system. The increasing inclusion of TRIPS-plus provisions in FTAs illustrates that
the status quo must change. The economic constraints of a strong IP regime are
very high, both economically and socially. Under TRIPS-plus provisions imposed by U.S. FTAs, countries are expected to take self-restrictive actions.
The Doha Declaration recognizes countries' rights to "promote access to
medicines for all" and represented a significant victory for developing countries
and global health. Ever since, health advocates and developing countries have
worked to live up to Doha's promise.
Still, a great deal of latitude depends upon the political willingness of countries to set their IP policy in accordance with their own national needs and priorities. Some countries participating in TPP negotiations have supported a superior
vision for intellectual property - one rooted in economics that also accounts for
the importance of public health, competition and safeguards against abuse. Pharmaceutical industry lobbyists, by contrast, drive the U.S. vision. The U.S. has
been isolated in negotiations, while others are in good company. To keep the
spirit of Doha alive, TPP countries must not trade away their more balanced rules
for the monopolistic rules dictated by the pharmaceutical industry.
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